elemental iron - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	elemental iron	go back to main search page
Accession:	CHEBI:82663	browse the term
Definition:	An elemental molecular entity in which all of the atoms have atomic number 26.

show annotations for term's descendants Sort by:
Rat (531 ) Mouse (528 ) Human (538 ) Chinchilla (0 ) Bonobo (0 ) Dog (2 ) Squirrel (0 ) Pig (0 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (528)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

decreases activity

ISO

ferbam results in decreased activity of HSD3B1 protein

NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110

G

transforming growth factor, beta 1

decreases activity

ISO

ferbam results in decreased activity of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

ferric ammonium citrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

increases activity
decreases activity

EXP

ferric ammonium citrate results in increased activity of ACO1 protein
ferric ammonium citrate results in decreased activity of ACO1 protein

PMID:11054110 PMID:18073202

NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338

G

aconitase 2, mitochondrial

multiple interactions
increases activity

ISO

ferric ammonium citrate inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; ferric ammonium citrate inhibits the reaction [Manganese results in decreased activity of ACO2 protein]
ferric ammonium citrate results in increased activity of ACO2 protein

NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334

G

acid phosphatase 5, tartrate resistant

increases expression
multiple interactions

ISO
EXP

ferric ammonium citrate results in increased expression of ACP5 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Niacin inhibits the reaction [ferric ammonium citrate results in increased expression of ACP5 protein]]; Niacin inhibits the reaction [ferric ammonium citrate results in increased expression of ACP5 protein]
Silybin inhibits the reaction [ferric ammonium citrate results in increased expression of ACP5 protein]

PMID:36087815 PMID:38081572

NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007

G

thymoma viral proto-oncogene 1

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

albumin

multiple interactions

EXP

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of ALB protein]

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

alkaline phosphatase, liver/bone/kidney

multiple interactions

EXP

ferric ammonium citrate results in decreased expression of and results in decreased activity of ALPL protein; Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of and results in decreased activity of ALPL protein]

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

annexin A3

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ANXA3 protein]

NCBI chr 5:96,941,257...96,993,825
Ensembl chr 5:96,941,198...96,993,825

G

Rho GDP dissociation inhibitor alpha

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ARHGDIA protein]

NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450

G

beclin 1, autophagy related

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of BECN1 protein; [Hydrogen Peroxide co-treated with [ferric ammonium citrate results in increased abundance of Iron]] results in increased expression of BECN1 protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

bone morphogenetic protein 6

multiple interactions

ISO

ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

caspase 3

increases cleavage
multiple interactions

ISO
EXP

ferric ammonium citrate results in increased cleavage of CASP3 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]

PMID:17191120 PMID:26318285 PMID:27481217

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

cyclin dependent kinase inhibitor 1A

multiple interactions
increases expression

ISO

ferric ammonium citrate inhibits the reaction [2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone results in decreased expression of CDKN1A protein]
ferric ammonium citrate results in increased expression of CDKN1A protein

PMID:12807743 PMID:38483099

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 2A

increases expression

ISO

ferric ammonium citrate results in increased expression of CDKN2A protein

NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890

G

collagen, type I, alpha 1

decreases expression

EXP

ferric ammonium citrate results in decreased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

C-X-C motif chemokine ligand 15

multiple interactions
increases secretion

ISO

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of CXCL8 mRNA]; ferric ammonium citrate inhibits the reaction [Ozone results in increased secretion of CXCL8 protein]
ferric ammonium citrate results in increased secretion of CXCL8 protein

PMID:10688536 PMID:24862973

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

dynamin 1-like

multiple interactions
decreases phosphorylation

EXP

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Cyclosporine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; ferric ammonium citrate results in decreased phosphorylation of and affects the localization of DNM1L protein; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]

PMID:26318285 PMID:27481217

NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823

G

endoplasmic reticulum to nucleus signalling 1

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]

NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678

G

endoplasmic reticulum protein 29

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ERP29 protein]

NCBI chr 5:121,582,816...121,590,537
Ensembl chr 5:121,566,653...121,590,569

G

coagulation factor III, tissue factor

increases expression
multiple interactions

ISO

ferric ammonium citrate results in increased expression of F3 mRNA
Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased expression of F3 mRNA]

NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697

G

ferritin heavy polypeptide 1

multiple interactions
increases expression

ISO

ferric ammonium citrate promotes the reaction [Palmitic Acid results in increased expression of FTH1 protein]
ferric ammonium citrate results in increased expression of FTH1 protein

PMID:32283200 PMID:38483099

NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462

G

ferritin light polypeptide 1

multiple interactions
increases expression

ISO
EXP

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA
ferric ammonium citrate results in increased expression of FTL protein
ferric ammonium citrate results in increased expression of FTL1 protein
SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA]

PMID:12393473 PMID:19913091 PMID:38483099

NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GAPDH protein]

NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430

G

galactosidase, beta 1

increases expression

ISO

ferric ammonium citrate results in increased expression of GLB1 protein

NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966

G

glyoxalase 1

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GLO1 protein]

NCBI chr17:30,811,835...30,831,633
Ensembl chr17:30,803,910...30,845,845

G

H2A.X variant histone

increases expression

ISO

ferric ammonium citrate results in increased expression of H2AX protein

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

hepcidin antimicrobial peptide

multiple interactions
decreases expression

ISO

Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

heme oxygenase 1

increases expression
multiple interactions

ISO

ferric ammonium citrate results in increased expression of HMOX1 protein
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ferric ammonium citrate results in increased expression of HMOX1 protein]

PMID:12393473 PMID:16439612

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heat shock protein 1A

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPA1A protein]

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 1-like

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA

NCBI chr17:35,191,679...35,198,204
Ensembl chr17:35,191,679...35,198,261

G

heat shock protein 9

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA

NCBI chr18:35,070,467...35,087,404
Ensembl chr18:35,070,467...35,087,410

G

heat shock protein 1 (chaperonin)

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPD1 protein]

NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402

G

interleukin 1 beta

multiple interactions

EXP

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of IL1B protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of IL6 mRNA]; ferric ammonium citrate inhibits the reaction [Ozone results in increased secretion of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]; Thapsigargin inhibits the reaction [ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

insulin II

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

G

iron responsive element binding protein 2

decreases expression
decreases activity

ISO
EXP

ferric ammonium citrate results in decreased expression of IREB2 protein
ferric ammonium citrate results in decreased activity of IREB2 protein

PMID:11054110 PMID:17469137 PMID:18073202

NCBI chr 9:54,769,942...54,819,812
Ensembl chr 9:54,771,073...54,819,814

G

lipocalin 2

multiple interactions

EXP

ferric ammonium citrate inhibits the reaction [bathophenanthroline disulfonic acid results in decreased expression of LCN2 protein]

NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

ISO

[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein
ferric ammonium citrate results in increased phosphorylation of MAPK1 protein

PMID:17191120 PMID:25858758

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 14

increases phosphorylation

ISO

ferric ammonium citrate results in increased phosphorylation of MAPK14 protein

NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

ISO

[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein
ferric ammonium citrate results in increased phosphorylation of MAPK3 protein

PMID:17191120 PMID:25858758

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

mitochondrial ribosomal protein S9

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of MRPS9 protein]

NCBI chr 1:42,890,393...42,944,843
Ensembl chr 1:42,890,393...42,944,843

G

metallothionein 2

multiple interactions

ISO

[ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

nuclear receptor coactivator 4

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased expression of NCOA4 protein]

NCBI chr14:31,881,884...31,901,210
Ensembl chr14:31,881,822...31,901,812

G

nitric oxide synthase 2, inducible

multiple interactions

ISO

[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

O-GlcNAcase

multiple interactions

EXP

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of OGA protein]

NCBI chr19:45,738,698...45,772,274
Ensembl chr19:45,738,698...45,772,276

G

procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of P4HA1 protein]

NCBI chr10:59,159,019...59,209,126
Ensembl chr10:59,159,118...59,209,126

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

pyruvate dehydrogenase (lipoamide) beta

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PDHB protein]

NCBI chr14:14,296,470...14,303,782
Ensembl chr14:14,296,748...14,303,777

G

phosphoglycerate kinase 1

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PGK1 protein]

NCBI chr X:105,230,706...105,247,305
Ensembl chr X:105,230,706...105,247,305

G

peripheral myelin protein 22

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA

NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373

G

peptidylprolyl isomerase A

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PPIA protein]

NCBI chr11:6,365,867...6,369,817
Ensembl chr11:6,365,443...6,369,817

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of PTGS2 mRNA]

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

receptor for activated C kinase 1

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of RACK1 protein]

NCBI chr11:48,691,187...48,697,068
Ensembl chr11:48,691,159...48,697,261

G

runt related transcription factor 2

decreases expression
multiple interactions

EXP

ferric ammonium citrate results in decreased expression of RUNX2 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Niacin inhibits the reaction [ferric ammonium citrate results in decreased expression of RUNX2 protein]]; Niacin inhibits the reaction [ferric ammonium citrate results in decreased expression of RUNX2 protein]; Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of RUNX2 protein]

PMID:36087815 PMID:38081572

NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684

G

sirtuin 1

multiple interactions
decreases expression

ISO
EXP

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]
ferric ammonium citrate results in decreased expression of SIRT1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Niacin inhibits the reaction [ferric ammonium citrate results in decreased expression of SIRT1 protein]]; Niacin inhibits the reaction [ferric ammonium citrate results in decreased expression of SIRT1 protein]; Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of SIRT1 protein]

PMID:34826546 PMID:36087815 PMID:38081572

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1

increases expression

EXP

ferric ammonium citrate results in increased expression of SLC11A1 mRNA

NCBI chr 1:74,414,318...74,429,974
Ensembl chr 1:74,414,354...74,425,221

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2

increases expression

EXP

ferric ammonium citrate results in increased expression of SLC11A2 mRNA

NCBI chr15:100,285,779...100,322,090
Ensembl chr15:100,285,779...100,322,953

G

solute carrier family 40 (iron-regulated transporter), member 1

increases expression
multiple interactions

EXP
ISO

ferric ammonium citrate results in increased expression of SLC40A1 mRNA
SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA]

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

superoxide dismutase 1, soluble

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of SOD1 mRNA]

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

multiple interactions
decreases expression

ISO
EXP

Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of SOD2 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Niacin inhibits the reaction [ferric ammonium citrate results in decreased expression of SOD2 protein]]; Niacin inhibits the reaction [ferric ammonium citrate results in decreased expression of SOD2 protein]; Silybin inhibits the reaction [ferric ammonium citrate results in decreased expression of SOD2 protein]

PMID:36087815 PMID:38081572

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

transferrin receptor 2

decreases expression

ISO

ferric ammonium citrate results in decreased expression of TFR2 protein

NCBI chr 5:137,568,127...137,586,344
Ensembl chr 5:137,568,102...137,585,743

G

transferrin receptor

decreases expression
multiple interactions

ISO
EXP

ferric ammonium citrate results in decreased expression of TFRC mRNA; ferric ammonium citrate results in decreased expression of TFRC protein
[ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA

PMID:11054110 PMID:12393473 PMID:16760464 PMID:18073202 PMID:25633564

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

G

tumor necrosis factor

multiple interactions

EXP

ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor protein D52-like 1

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of TPD52L1 protein]

NCBI chr10:31,208,369...31,321,989
Ensembl chr10:31,208,372...31,321,954

G

transferrin

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron]

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

transformation related protein 53

increases expression

ISO

ferric ammonium citrate results in increased expression of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

voltage-dependent anion channel 2

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of VDAC2 protein]

NCBI chr14:21,881,629...21,895,947
Ensembl chr14:21,875,306...21,895,947

G

X-box binding protein 1

multiple interactions

ISO

ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased expression of XBP1 protein]

NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family C member 1

multiple interactions

EXP

ABCC1 protein promotes the reaction [Nitric Oxide results in increased secretion of Iron]

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP binding cassette subfamily G member 2 (Junior blood group)

affects metabolic processing

EXP

ABCG2 protein affects the metabolism of Iron

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

acyl-Coenzyme A binding domain containing 3

multiple interactions

ISO

Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]

NCBI chr 1:180,553,608...180,581,769
Ensembl chr 1:180,553,608...180,581,769

G

acetylcholinesterase

multiple interactions

ISO

[teferrol results in increased abundance of Iron] which results in decreased activity of ACHE protein

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

aconitase 1

affects metabolic processing
multiple interactions

EXP
ISO

ACO1 protein affects the metabolism of Iron
Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein]
[Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein

PMID:15893546 PMID:16039939 PMID:16877034 PMID:17194590

NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338

G

aconitase 2, mitochondrial

multiple interactions
increases activity

ISO

[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical; [Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron; ACO2 protein affects the reaction [Paraquat results in increased abundance of Iron]; Iron deficiency promotes the reaction [Clofibrate results in increased expression of ACO2 protein]; Iron inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; Iron inhibits the reaction [Manganese results in decreased activity of ACO2 protein]
Iron results in increased activity of ACO2 protein

PMID:9675333 PMID:11969379 PMID:16162655 PMID:21517855

NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334

G

acyl-CoA synthetase family member 2

decreases expression

ISO

Iron deficiency results in decreased expression of ACSF2 mRNA

NCBI chr11:94,447,928...94,492,822
Ensembl chr11:94,447,928...94,492,697

G

acyl-CoA synthetase long-chain family member 1

decreases expression

ISO

Iron deficiency results in decreased expression of ACSL1 mRNA

NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088

G

acyl-CoA synthetase long-chain family member 3

decreases expression

ISO

Iron deficiency results in decreased expression of ACSL3 mRNA

NCBI chr 1:78,635,600...78,685,462
Ensembl chr 1:78,635,542...78,685,460

G

adhesion G protein-coupled receptor G1

decreases expression

ISO

Iron deficiency results in decreased expression of ADGRG1 mRNA

NCBI chr 8:95,701,321...95,740,836
Ensembl chr 8:95,701,379...95,740,845

G

alpha hemoglobin stabilizing protein

multiple interactions

ISO

AHSP protein binds to and affects the folding of and affects the stability of [HBA1 protein binds to Iron]

NCBI chr 7:127,902,016...127,902,926
Ensembl chr 7:127,901,969...127,902,930

G

A kinase anchor protein 13

decreases expression

ISO

Iron deficiency results in decreased expression of AKAP13 mRNA

NCBI chr 7:75,105,271...75,404,357
Ensembl chr 7:75,105,282...75,404,357

G

thymoma viral proto-oncogene 1

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]

PMID:17172471 PMID:32828744 PMID:33580994

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

aminolevulinic acid synthase 2, erythroid

increases expression

EXP

Iron results in increased expression of ALAS2 mRNA

NCBI chr X:149,330,443...149,353,614
Ensembl chr X:149,330,371...149,353,634

G

albumin

multiple interactions

ISO

ALB protein affects the reaction [[Iron co-treated with Bicarbonates] results in increased abundance of Malondialdehyde]; ALB protein inhibits the reaction [[Iron co-treated with Phosphates] results in increased abundance of Malondialdehyde]

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldolase C, fructose-bisphosphate

decreases expression

ISO

Iron deficiency results in decreased expression of ALDOC mRNA

NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607

G

ankyrin repeat domain 22

increases expression

ISO

Iron deficiency results in increased expression of ANKRD22 mRNA

NCBI chr19:34,099,949...34,143,441
Ensembl chr19:34,098,869...34,143,453

G

ankyrin repeat domain 37

increases expression

ISO
EXP

Iron deficiency results in increased expression of ANKRD37 mRNA

PMID:16629162 PMID:23776592

NCBI chr 8:46,449,945...46,452,904
Ensembl chr 8:46,449,939...46,458,744

G

annexin A1

decreases expression

ISO

Iron deficiency results in decreased expression of ANXA1 mRNA

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

annexin A2

increases expression

ISO

Iron deficiency results in increased expression of ANXA2 mRNA

NCBI chr 9:69,360,978...69,399,074
Ensembl chr 9:69,360,902...69,399,077

G

adaptor-related protein complex AP-1, sigma 3

decreases expression

ISO

Iron deficiency results in decreased expression of AP1S3 mRNA

NCBI chr 1:79,584,593...79,649,736
Ensembl chr 1:79,584,593...79,649,689

G

adaptor-related protein complex 2, alpha 1 subunit

multiple interactions

ISO

[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of AP2A1 mRNA

NCBI chr 7:44,549,797...44,578,914
Ensembl chr 7:44,549,797...44,578,920

G

apolipoprotein E

increases response to substance

ISO

APOE gene polymorphism results in increased susceptibility to Iron

NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113

G

apolipoprotein H

decreases expression

ISO

Iron deficiency results in decreased expression of APOH mRNA

NCBI chr11:108,286,123...108,305,222
Ensembl chr11:108,234,180...108,305,222

G

amyloid beta precursor protein

increases expression
increases uptake

ISO

Iron results in increased expression of APP mRNA
Iron results in increased uptake of APP protein

PMID:15993987 PMID:16308480

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

aquaporin 4

increases expression
multiple interactions

ISO
EXP

Iron deficiency results in increased expression of AQP4 mRNA
[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 mRNA; [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein; SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; U 0126 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; Vitamin E inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]

PMID:16629162 PMID:30914277

NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039

G

AT-rich interaction domain 3B

increases expression

ISO

Iron deficiency results in increased expression of ARID3B mRNA

NCBI chr 9:57,697,636...57,744,130
Ensembl chr 9:57,697,636...57,744,076

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

ISO

ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter]

NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551

G

arrestin domain containing 3

increases expression

ISO

Iron deficiency results in increased expression of ARRDC3 mRNA

NCBI chr13:81,031,508...81,044,161
Ensembl chr13:81,031,503...81,044,161

G

ataxia telangiectasia mutated

affects response to substance
multiple interactions
affects abundance

ISO
EXP

ATM protein affects the susceptibility to Iron
Iron results in increased phosphorylation of and results in increased activity of ATM protein
ATM protein affects the abundance of Iron

PMID:15336622 PMID:16959548

NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040

G

ATPase, copper transporting, alpha polypeptide

affects metabolic processing
multiple interactions
increases response to substance
decreases oxidation
affects transport
increases expression

EXP
ISO

ATP7A protein mutant form affects the metabolism of Iron
[ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Iron; ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]; Iron deficiency inhibits the reaction [ATP7A gene mutant form results in decreased oxidation of Iron]
ATP7A gene mutant form results in increased susceptibility to Iron deficiency
ATP7A mutant form affects the transport of Iron
Iron deficiency results in increased expression of ATP7A mRNA
[Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper
Iron deficiency results in increased expression of ATP7A; Iron deficiency results in increased expression of ATP7A mRNA; Iron deficiency results in increased expression of ATP7A protein

PMID:16629162 PMID:21852364 PMID:23174565 PMID:23776592 PMID:23814049 More...

NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532

G

ATPase, copper transporting, beta polypeptide

increases abundance

ISO

ATP7B gene mutant form results in increased abundance of Iron

NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321

G

beta-2 microglobulin

multiple interactions
affects metabolic processing

ISO
EXP

[HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron
B2M protein affects the metabolism of Iron

PMID:16841247 PMID:17194590

NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564

G

BCL2-associated agonist of cell death

multiple interactions

ISO

[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]

NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267

G

BCL2-associated X protein

multiple interactions

ISO
EXP

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]

PMID:30626086 PMID:33285147 PMID:33393188

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 10

multiple interactions

ISO

[Arsenic co-treated with Iron] results in increased expression of BCL10 mRNA

NCBI chr 3:145,630,017...145,640,121
Ensembl chr 3:145,628,559...145,640,111

G

B cell leukemia/lymphoma 2

multiple interactions

ISO

[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]

PMID:19620254 PMID:33285147

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

BCL2-like 1

multiple interactions

ISO

[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]

PMID:19620254 PMID:27916511 PMID:30626086

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

B cell leukemia/lymphoma 3

increases expression

ISO

Iron deficiency results in increased expression of BCL3 mRNA

NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695

G

beclin 1, autophagy related

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of BECN1 protein; [Hydrogen Peroxide co-treated with [ferric ammonium citrate results in increased abundance of Iron]] results in increased expression of BECN1 protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

bone morphogenetic protein 6

increases abundance
decreases expression
decreases abundance
increases expression

EXP
ISO

BMP6 gene mutant form results in increased abundance of Iron
Iron deficiency results in decreased expression of BMP6 mRNA
BMP6 protein results in decreased abundance of Iron
Iron results in increased expression of BMP6 mRNA

PMID:19252486 PMID:19252488 PMID:20164366

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

BCL2/adenovirus E1B interacting protein 3

increases expression

EXP

Iron deficiency results in increased expression of BNIP3 mRNA

NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248

G

calcium channel, voltage-dependent, L type, alpha 1C subunit

multiple interactions

ISO

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein]

NCBI chr 6:118,564,201...119,174,345
Ensembl chr 6:118,564,201...119,173,851

G

calreticulin

increases expression

ISO

Iron results in increased expression of CALR mRNA; Iron results in increased expression of CALR protein

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

G

calcium/calmodulin-dependent protein kinase II, delta

multiple interactions

ISO

[Arsenic co-treated with Iron] results in increased expression of CAMK2D mRNA

NCBI chr 3:126,389,136...126,639,975
Ensembl chr 3:126,389,951...126,639,975

G

caspase 3

multiple interactions

ISO
EXP

3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; [Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CASP3 protein

PMID:19620254 PMID:27916511 PMID:30626086 PMID:31678598 PMID:32828744 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions
decreases activity

EXP
ISO

Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein]; Iron promotes the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [mezerein results in decreased activity of CAT protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein]
[Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of CAT protein; [ferrocene results in increased abundance of Iron] which results in decreased expression of CAT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein; [teferrol results in increased abundance of Iron] which results in increased activity of CAT protein; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CAT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein]; leonurine inhibits the reaction [Iron results in decreased activity of CAT protein]

PMID:12065085 PMID:12067571 PMID:12504893 PMID:17176674 PMID:20100038 More...

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

caveolin 1, caveolae protein

affects localization

ISO

Iron affects the localization of CAV1 protein

NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

ISO

Iron deficiency results in increased expression of CCL2 mRNA
[Iron co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA; Iron promotes the reaction [[Copper co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA]

PMID:20302851 PMID:20368581

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 3

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CCL3 mRNA

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 5

increases expression

ISO

Iron deficiency results in increased expression of CCL5 mRNA

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

cyclin A2

multiple interactions

ISO

[Arsenic co-treated with Iron] results in decreased expression of CCNA2 mRNA

NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299

G

cyclin D1

increases expression

EXP
ISO

Iron results in increased expression of CCND1
Iron deficiency results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1; Iron results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1 protein

PMID:16629162 PMID:16890145 PMID:22649188

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin G2

increases expression

ISO

Iron deficiency results in increased expression of CCNG2 mRNA

NCBI chr 5:93,415,432...93,424,090
Ensembl chr 5:93,415,116...93,424,090

G

cell cycle progression 1

increases expression

ISO

Iron deficiency results in increased expression of CCPG1 mRNA

NCBI chr 9:72,892,692...72,923,622
Ensembl chr 9:72,892,711...72,923,622

G

centriole, cilia and spindle associated protein

increases expression

ISO

Iron deficiency results in increased expression of CCSAP mRNA

NCBI chr 8:124,566,712...124,586,948
Ensembl chr 8:124,567,570...124,586,948

G

CD109 antigen

increases expression

ISO

Iron deficiency results in increased expression of CD109 mRNA

NCBI chr 9:78,522,828...78,623,542
Ensembl chr 9:78,522,828...78,623,535

G

CD14 antigen

multiple interactions
increases expression

ISO

Acetylcysteine inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; Vitamin D promotes the reaction [Iron deficiency results in increased expression of CD14 protein]

NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851

G

CD1d1 antigen

decreases expression

ISO

Iron deficiency results in decreased expression of CD1D1 mRNA

NCBI chr 3:86,903,141...86,919,665
Ensembl chr 3:86,903,141...86,906,748

G

CD300A molecule

increases expression

ISO

Iron deficiency results in increased expression of CD300A mRNA

NCBI chr11:114,780,006...114,792,772
Ensembl chr11:114,780,867...114,795,480

G

CD36 molecule

decreases expression

ISO

Iron deficiency results in decreased expression of CD36 mRNA

PMID:16629162 PMID:19821111

NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799

G

CD70 antigen

increases expression

ISO

Iron deficiency results in increased expression of CD70 mRNA

NCBI chr17:57,452,997...57,456,777
Ensembl chr17:57,452,997...57,456,777

G

CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)

decreases expression

ISO

Iron deficiency results in decreased expression of CD74 mRNA

NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724

G

CDP-diacylglycerol--inositol 3-phosphatidyltransferase

decreases expression

ISO

Iron deficiency results in decreased expression of CDIPT mRNA

NCBI chr 7:126,575,630...126,579,671
Ensembl chr 7:126,575,086...126,579,673

G

cyclin dependent kinase inhibitor 1A

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CDKN1A mRNA

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 1C

decreases expression

ISO

Iron deficiency results in decreased expression of CDKN1C mRNA

NCBI chr 7:143,012,076...143,014,735
Ensembl chr 7:143,012,076...143,014,787

G

cyclin dependent kinase inhibitor 2D

increases expression

ISO

Iron deficiency results in increased expression of CDKN2D mRNA

NCBI chr 9:21,199,759...21,202,553
Ensembl chr 9:21,199,706...21,202,703

G

cysteine dioxygenase 1, cytosolic

multiple interactions

ISO

Iron binds to and results in increased activity of CDO1 protein

NCBI chr18:46,846,260...46,861,569
Ensembl chr18:46,846,260...46,861,462

G

CMT1A duplicated region transcript 4

increases expression

ISO

Iron deficiency results in increased expression of CDRT4 mRNA

NCBI chr11:62,842,019...62,883,921
Ensembl chr11:62,842,019...62,883,921

G

CDP-diacylglycerol synthase 1

decreases expression

ISO

Iron deficiency results in decreased expression of CDS1 mRNA

NCBI chr 5:101,913,001...101,971,724
Ensembl chr 5:101,912,996...101,971,724

G

carboxyl ester lipase

increases expression

ISO

Iron deficiency results in increased expression of CEL mRNA

NCBI chr 2:28,445,831...28,453,415
Ensembl chr 2:28,445,807...28,453,415

G

checkpoint kinase 2

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of CHEK2 mRNA

NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011

G

chitinase 3 like 1

decreases expression

ISO

Iron deficiency results in decreased expression of CHI3L1 mRNA

NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919

G

cholinergic receptor, nicotinic, delta polypeptide

multiple interactions

ISO

[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of CHRND mRNA

NCBI chr 1:87,118,319...87,127,792
Ensembl chr 1:87,118,329...87,127,792

G

conserved helix-loop-helix ubiquitous kinase

multiple interactions

ISO

deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein]

PMID:17172471 PMID:33285147

NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919

G

claudin 2

increases expression

ISO

Iron deficiency results in increased expression of CLDN2 mRNA

NCBI chr X:138,701,552...138,712,135
Ensembl chr X:138,701,577...138,712,135

G

colipase, pancreatic

increases expression

ISO

Iron deficiency results in increased expression of CLPS mRNA

NCBI chr17:28,777,184...28,779,740
Ensembl chr17:28,777,123...28,779,740

G

calponin 3, acidic

increases expression

ISO

Iron deficiency results in increased expression of CNN3 mRNA

NCBI chr 3:121,220,190...121,251,854
Ensembl chr 3:121,220,146...121,251,856

G

collagen, type I, alpha 1

multiple interactions

ISO

Iron promotes the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA]

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

ceruloplasmin

affects binding
decreases export
increases oxidation
multiple interactions
increases activity
increases abundance
increases expression

ISO
EXP

CP protein binds to [TF protein binds to Iron]
CP gene mutant form results in decreased export of Iron
CP protein results in increased oxidation of Iron
[CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter]
[CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of CP protein]
Iron deficiency results in increased expression of CP protein; Iron deficiency results in increased expression of CP protein modified form
[Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CP protein]

PMID:10777486 PMID:12572680 PMID:16988052 PMID:19061943 PMID:20655381 More...

NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309

G

colony stimulating factor 2 (granulocyte-macrophage)

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CSF2 mRNA

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

cleavage stimulation factor, 3' pre-RNA subunit 2, tau

decreases expression

ISO

Iron deficiency results in decreased expression of CSTF2T mRNA

NCBI chr19:31,060,241...31,063,992
Ensembl chr19:31,060,237...31,064,469

G

catenin beta interacting protein 1

decreases expression

ISO

Iron deficiency results in decreased expression of CTNNBIP1 mRNA

NCBI chr 4:149,602,698...149,650,894
Ensembl chr 4:149,602,693...149,650,894

G

cathepsin K

multiple interactions

EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CTSK protein; Acetylcysteine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CTSK protein]; Deferoxamine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CTSK protein]

NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673

G

C-X-C motif chemokine ligand 1

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CXCL1 protein

NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974

G

C-X-C motif chemokine ligand 15

multiple interactions
increases expression
increases secretion

ISO
EXP

Iron inhibits the reaction [Asbestos, Amphibole results in increased expression of CXCL8]
Iron analog results in increased expression of CXCL8 mRNA
Iron results in increased secretion of CXCL15 protein

PMID:21605006 PMID:23724284 PMID:26416317

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 2

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CXCL2 protein

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

cytochrome b reductase 1

decreases expression
increases expression

ISO
EXP

Iron results in decreased expression of CYBRD1 protein
Iron results in increased expression of CYBRD1 protein
Iron deficiency results in increased expression of CYBRD1 mRNA

PMID:16629162 PMID:18815723 PMID:19821111 PMID:21540277 PMID:23776592 More...

NCBI chr 2:70,948,398...70,973,270
Ensembl chr 2:70,948,267...70,973,270

G

cytochrome P450, family 2, subfamily a, polypeptide 5

increases expression

ISO

Iron results in increased expression of CYP2A6 protein

NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973

G

cytohesin 1 interacting protein

increases expression

ISO

Iron deficiency results in increased expression of CYTIP mRNA

NCBI chr 2:58,019,151...58,085,559
Ensembl chr 2:58,019,149...58,085,544

G

death associated protein-like 1

decreases expression

ISO

Iron deficiency results in decreased expression of DAPL1 mRNA

NCBI chr 2:59,314,997...59,335,364
Ensembl chr 2:59,314,997...59,335,364

G

Fas death domain-associated protein

increases expression

ISO

Iron results in increased expression of DAXX mRNA

NCBI chr17:34,128,379...34,134,564
Ensembl chr17:34,128,388...34,134,564

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

ISO

Iron deficiency results in increased expression of DDIT3 mRNA
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of DDIT3 mRNA

PMID:20368581 PMID:22198552

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

defensin, alpha, 3

decreases expression

ISO

Iron deficiency results in decreased expression of DEFA3 mRNA

NCBI chr 8:21,777,425...21,778,393
Ensembl chr 8:21,777,425...21,778,393

G

diacylglycerol kinase, alpha

increases expression

ISO

Iron deficiency results in increased expression of DGKA mRNA

NCBI chr10:128,556,000...128,581,002
Ensembl chr10:128,556,003...128,580,724

G

deleted in liver cancer 1

increases expression

ISO

Iron deficiency results in increased expression of DLC1 mRNA

NCBI chr 8:37,034,893...37,420,343
Ensembl chr 8:37,034,905...37,420,297

G

dedicator of cytokinesis 10

increases expression

ISO

Iron deficiency results in increased expression of DOCK10 mRNA

NCBI chr 1:80,478,785...80,736,482
Ensembl chr 1:80,478,790...80,736,244

G

dopamine receptor D1

multiple interactions

ISO

[manganese chloride co-treated with Iron deficiency] results in decreased expression of DRD1 protein

NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724

G

dopamine receptor D2

multiple interactions

ISO

[manganese chloride co-treated with Iron deficiency] results in increased expression of DRD2 protein

NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477

G

E2F transcription factor 1

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of E2F1 mRNA

NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812

G

E2F transcription factor 8

increases expression

ISO

Iron deficiency results in increased expression of E2F8 mRNA

NCBI chr 7:48,516,177...48,531,821
Ensembl chr 7:48,516,177...48,531,344

G

endothelin 1

multiple interactions

ISO

[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein]

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

eukaryotic elongation factor-2 kinase

increases expression

ISO

Iron deficiency results in increased expression of EEF2K mRNA

NCBI chr 7:120,442,080...120,506,441
Ensembl chr 7:120,442,054...120,506,673

G

epidermal growth factor receptor

multiple interactions

ISO

[Arsenic co-treated with Iron] results in decreased expression of EGFR mRNA

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

egl-9 family hypoxia-inducible factor 1

affects binding

ISO

Iron binds to EGLN1 protein

NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063

G

egl-9 family hypoxia-inducible factor 3

increases expression

ISO

Iron deficiency results in increased expression of EGLN3 mRNA

NCBI chr12:54,225,767...54,250,660
Ensembl chr12:54,225,767...54,250,646

G

early growth response 1

increases expression
multiple interactions

ISO

Iron deficiency results in increased expression of EGR1 mRNA
[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of EGR1 mRNA

PMID:16629162 PMID:24619124

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

elastase, neutrophil expressed

decreases expression

ISO

Iron deficiency results in decreased expression of ELANE mRNA

NCBI chr10:79,722,146...79,724,050
Ensembl chr10:79,722,081...79,724,049

G

epithelial membrane protein 1

increases expression

ISO

Iron deficiency results in increased expression of EMP1 mRNA

NCBI chr 6:135,339,548...135,360,171
Ensembl chr 6:135,339,543...135,360,171

G

endothelial PAS domain protein 1

multiple interactions
increases expression

ISO

Iron inhibits the reaction [galangin results in increased expression of EPAS1 protein]; Iron inhibits the reaction [Quercetin results in increased expression of EPAS1 protein]
Iron deficiency results in increased expression of EPAS1 protein

PMID:17973296 PMID:23814049

NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838

G

erythropoietin

affects response to substance

ISO

Iron affects the susceptibility to EPO protein

NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504

G

exocyst complex component 6

affects metabolic processing

EXP

EXOC6 protein affects the metabolism of Iron

NCBI chr19:37,525,181...37,672,499
Ensembl chr19:37,509,327...37,672,507

G

coagulation factor XIII, A1 subunit

decreases expression

ISO

Iron deficiency results in decreased expression of F13A1 mRNA

NCBI chr13:37,051,150...37,234,220
Ensembl chr13:37,051,152...37,234,220

G

coagulation factor II

decreases activity

ISO

Iron results in decreased activity of F2 protein

NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759

G

fatty acid binding protein 2, intestinal

increases expression

ISO

Iron deficiency results in increased expression of FABP2 mRNA

NCBI chr 3:122,688,721...122,693,155
Ensembl chr 3:122,688,721...122,693,155

G

fatty acid binding protein 6

increases expression

ISO

Iron deficiency results in increased expression of FABP6 mRNA

NCBI chr11:43,486,867...43,492,389
Ensembl chr11:43,486,876...43,492,367

G

family with sequence similarity 117, member B

increases expression

ISO

Iron deficiency results in increased expression of FAM117B mRNA

NCBI chr 1:59,952,165...60,024,507
Ensembl chr 1:59,952,165...60,024,505

G

FAM20C, golgi associated secretory pathway kinase

decreases expression

ISO

Iron deficiency results in decreased expression of FAM20C mRNA

NCBI chr 5:138,740,836...138,795,818
Ensembl chr 5:138,740,269...138,795,832

G

F-box and WD-40 domain protein 5

multiple interactions

ISO

[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of FBXW5 mRNA

NCBI chr 2:25,390,762...25,395,482
Ensembl chr 2:25,390,762...25,395,483

G

ferrochelatase

multiple interactions

EXP
ISO

[Aminolevulinic Acid results in decreased activity of FECH protein] which results in increased abundance of Iron; [Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron; [Porphobilinogen results in decreased activity of FECH protein] which results in increased abundance of Iron; heme arginate inhibits the reaction [[Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron]
[pyridoxal isonicotinoyl hydrazone results in decreased abundance of Iron] which results in decreased expression of FECH protein

PMID:15078340 PMID:30517741

NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322

G

flap structure specific endonuclease 1

multiple interactions

ISO

Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein]

NCBI chr19:10,176,496...10,181,757
Ensembl chr19:10,176,496...10,181,533

G

flotillin 1

increases expression

ISO

Iron deficiency results in increased expression of FLOT1 mRNA

NCBI chr17:36,134,243...36,143,674
Ensembl chr17:36,134,122...36,143,683

G

fructosamine 3 kinase

multiple interactions

ISO

[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FN3K mRNA

NCBI chr11:121,325,779...121,341,316
Ensembl chr11:121,325,739...121,341,317

G

farnesyltransferase, CAAX box, beta

increases expression

ISO

Iron deficiency results in increased expression of FNTB mRNA

NCBI chr12:76,884,014...76,968,188
Ensembl chr12:76,812,363...76,968,186

G

FBJ osteosarcoma oncogene

multiple interactions

ISO

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein; [Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FOS mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]

PMID:24619124 PMID:32828744 PMID:33580994

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

ferritin heavy polypeptide 1

affects abundance
affects metabolic processing
decreases expression
multiple interactions
affects binding
increases expression

EXP
ISO

FTH1 protein affects the abundance of Iron
FTH1 protein affects the metabolism of Iron
Iron results in decreased expression of FTH1 mRNA
[[NBD peptide, mouse results in decreased expression of FTH1 mRNA] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]
[CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein; Deferoxamine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein]; FTH1 protein inhibits the reaction [Iron results in increased abundance of Reactive Oxygen Species]
Iron binds to FTH1 protein
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA; Iron deficiency promotes the reaction [Vitamin A deficiency results in decreased expression of FTH1 protein]
Iron results in increased expression of FTH1 mRNA

PMID:15893546 PMID:16424395 PMID:16448386 PMID:16988052 PMID:17070541 More...

NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462

G

ferritin light polypeptide 1

multiple interactions
decreases uptake
affects binding
decreases expression
increases expression

ISO
EXP

2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]
FTL protein mutant form results in decreased uptake of Iron
[CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of FTL1 mRNA]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of FTL1 mRNA]
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA]
Iron results in decreased expression of FTL1 mRNA

PMID:12393473 PMID:12644586 PMID:15893546 PMID:16424395 PMID:16822677 More...

NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308

G

ferritin mitochondrial

multiple interactions
affects binding
affects localization

ISO
EXP

2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [diallyl trisulfide results in decreased expression of FTMT protein] which results in increased abundance of Iron; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]
FTMT protein affects the localization of Iron

PMID:12644586 PMID:16757684 PMID:21616139

NCBI chr18:52,464,608...52,466,068
Ensembl chr18:52,464,621...52,466,068

G

frataxin

increases abundance
increases metabolic processing
affects binding
affects metabolic processing

ISO
EXP

FXN gene mutant form results in increased abundance of Iron
FXN protein results in increased metabolism of Iron
Iron binds to FXN protein
FXN protein affects the metabolism of Iron

PMID:16120311 PMID:16911956 PMID:17101455 PMID:17194590

NCBI chr19:24,236,909...24,257,954
Ensembl chr19:24,238,817...24,257,969

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

ISO

Iron deficiency results in decreased expression of G6PC1 mRNA

NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729

G

gamma-aminobutyric acid type B receptor subunit 2

multiple interactions
decreases expression

ISO

[Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 protein
Iron deficiency results in decreased expression of GABBR2 mRNA; Iron deficiency results in decreased expression of GABBR2 protein

NCBI chr 4:46,662,318...46,991,714
Ensembl chr 4:46,662,305...46,991,873

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions
increases expression
decreases expression

ISO

[Iron deficiency co-treated with manganese chloride] results in increased expression of GABRA1 protein
Iron deficiency results in increased expression of GABRA1 protein
Iron deficiency results in decreased expression of GABRA1 mRNA

NCBI chr11:42,021,766...42,073,893
Ensembl chr11:42,021,766...42,073,757

G

GAR1 ribonucleoprotein

increases expression

ISO

Iron deficiency results in increased expression of GAR1 mRNA

NCBI chr 3:129,618,561...129,625,045
Ensembl chr 3:129,618,561...129,625,045

G

growth arrest specific 1

multiple interactions

ISO

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA

NCBI chr13:60,322,219...60,325,179
Ensembl chr13:60,322,219...60,325,179

G

growth arrest specific 7

increases expression

ISO

Iron deficiency results in increased expression of GAS7 mRNA

NCBI chr11:67,344,083...67,579,818
Ensembl chr11:67,345,917...67,575,800

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
decreases expression
increases activity

ISO

Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLC mRNA]
Iron results in increased activity of GCLC protein
Iron results in decreased expression of GCLC protein
leonurine inhibits the reaction [Iron results in decreased expression of GCLC protein]

PMID:17189828 PMID:19073151 PMID:35247364

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutamate-cysteine ligase, modifier subunit

multiple interactions
decreases expression

ISO

Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLM mRNA]

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

gastrokine 1

increases expression

ISO

Iron deficiency results in increased expression of GKN1 mRNA

NCBI chr 6:87,322,635...87,327,897
Ensembl chr 6:87,322,632...87,327,924

G

gastrokine 2

increases expression

ISO

Iron deficiency results in increased expression of GKN2 mRNA

NCBI chr 6:87,350,347...87,356,476
Ensembl chr 6:87,350,339...87,356,479

G

GLI-Kruppel family member GLI3

multiple interactions

ISO

[Arsenic co-treated with Iron] results in decreased expression of GLI3 mRNA

NCBI chr13:15,638,308...15,904,611
Ensembl chr13:15,637,820...15,904,611

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions
increases activity

ISO

Capsaicin inhibits the reaction [Iron results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [Iron results in increased activity of GOT1 protein]

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glycerol-3-phosphate acyltransferase, mitochondrial

increases expression

ISO

Iron deficiency results in increased expression of GPAM mRNA

NCBI chr19:55,056,067...55,115,666
Ensembl chr19:55,055,700...55,115,670

G

G protein-coupled receptor 34

increases expression

ISO

Iron deficiency results in increased expression of GPR34 mRNA

NCBI chr X:13,489,777...13,507,098
Ensembl chr X:13,498,328...13,507,097

G

G protein-coupled receptor, family C, group 5, member A

increases expression

ISO

Iron deficiency results in increased expression of GPRC5A mRNA

NCBI chr 6:135,042,660...135,061,707
Ensembl chr 6:135,042,649...135,061,707

G

glutamic pyruvic transaminase, soluble

multiple interactions
increases activity

ISO
EXP

[ferrocene results in increased abundance of Iron] which results in increased expression of GPT protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein; Capsaicin inhibits the reaction [Iron results in increased activity of GPT protein]; Curcumin inhibits the reaction [Iron results in increased activity of GPT protein]; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]; leonurine inhibits the reaction [Iron results in increased activity of GPT protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]
Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]

PMID:16956363 PMID:20100038 PMID:27916511 PMID:32828744 PMID:33580994 More...

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 1

multiple interactions
decreases response to substance

ISO
EXP

[Iron co-treated with Hydrogen Peroxide] results in decreased expression of and results in decreased activity of GPX1 protein
GPX1 protein results in decreased susceptibility to Iron

PMID:16721761 PMID:17280487

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

glutathione peroxidase 2

increases expression
affects expression

ISO

Iron deficiency results in increased expression of GPX2 mRNA
Iron affects the expression of GPX2 mRNA

PMID:16629162 PMID:24388910

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

glutathione peroxidase 4

decreases expression
multiple interactions

ISO

Iron results in decreased expression of GPX4 protein
leonurine inhibits the reaction [Iron results in decreased expression of GPX4 protein]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glycogen synthase kinase 3 beta

multiple interactions

ISO

[SB 216763 results in decreased activity of GSK3B protein] results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]

NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446

G

glutathione reductase

multiple interactions
decreases activity
decreases expression
affects activity

EXP
ISO

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GSR protein; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein]
[Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of GSR protein; leonurine inhibits the reaction [Iron results in decreased expression of GSR protein]
Iron results in decreased activity of GSR protein
Iron affects the activity of GSR protein

PMID:12067571 PMID:12504893 PMID:17176674 PMID:20020847 PMID:24388910 More...

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

glutathione synthetase

multiple interactions
decreases expression

ISO

Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GSS mRNA]

NCBI chr 2:155,405,101...155,434,730
Ensembl chr 2:155,405,101...155,434,730

G

glutathione S-transferase, alpha 1 (Ya)

multiple interactions
decreases expression
increases expression

ISO
EXP

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTA5 mRNA
Iron results in decreased expression of GSTA1 protein
Iron results in increased expression of GSTA1 mRNA; Iron results in increased expression of GSTA1 protein

PMID:11755321 PMID:20302851

NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966

G

glutathione S-transferase, alpha 2 (Yc2)

multiple interactions

ISO

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of GSTA2 mRNA

NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070

G

glutathione S-transferase, alpha 4

multiple interactions
increases expression

ISO
EXP

Iron results in increased expression of and results in increased activity of GSTA4 protein
Iron results in increased expression of GSTA4 mRNA; Iron results in increased expression of GSTA4 protein

PMID:7878679 PMID:11755321

NCBI chr 9:78,099,248...78,116,631
Ensembl chr 9:78,090,056...78,116,631

G

glutathione S-transferase, mu 1

decreases expression
increases expression

EXP

Iron results in decreased expression of GSTM1 protein
Iron results in increased expression of GSTM1 mRNA; Iron results in increased expression of GSTM1 protein

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase, mu 5

multiple interactions

ISO

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTM3 mRNA

NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002

G

histocompatibility 2, class II antigen A, beta 1

increases expression

ISO

Iron deficiency results in increased expression of RT1-BB mRNA

NCBI chr17:34,482,201...34,488,392
Ensembl chr17:34,476,663...34,488,393

G

histocompatibility 2, class II antigen E beta

increases expression

ISO

Iron deficiency results in increased expression of RT1-DB1 mRNA

NCBI chr17:34,524,841...34,535,648
Ensembl chr17:34,524,841...34,535,648

G

H3.4 histone, cluster member

increases methylation
multiple interactions

ISO

Iron results in increased methylation of H3-4 protein
[[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein

PMID:16603237 PMID:21385672

NCBI chr11:58,852,537...58,853,099
Ensembl chr11:58,852,599...58,853,364

G

hepcidin antimicrobial peptide

decreases secretion
multiple interactions
increases expression
affects metabolic processing
decreases expression
affects expression

ISO
EXP

HAMP protein results in decreased secretion of Iron
[IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]
Iron results in increased expression of HAMP mRNA
[Acetaminophen results in decreased expression of HAMP mRNA] which results in increased abundance of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of HAMP mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of HAMP protein; Deferoxamine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of HAMP protein]; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of HAMP mRNA]
HAMP protein affects the metabolism of Iron
Iron deficiency results in decreased expression of HAMP mRNA
Iron affects the expression of HAMP mRNA
Iron results in increased expression of HAMP protein

PMID:11113132 PMID:16460831 PMID:16574947 PMID:16648237 PMID:17116712 More...

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

hemoglobin alpha, adult chain 1

multiple interactions

ISO

AHSP protein binds to and affects the folding of and affects the stability of [HBA1 protein binds to Iron]

NCBI chr11:32,233,672...32,234,486
Ensembl chr11:32,233,511...32,234,465

G

hemoglobin, beta adult major chain

multiple interactions
affects abundance

EXP

[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA
HBB-B1 protein affects the abundance of Iron

G

hemoglobin, beta adult minor chain

multiple interactions
affects abundance

EXP

[HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA
HBB-B2 protein affects the abundance of Iron

G

histone deacetylase 8

multiple interactions

ISO

Iron binds to and results in increased activity of HDAC8 protein

NCBI chr X:101,328,244...101,549,005
Ensembl chr X:101,328,245...101,548,965

G

hephaestin

affects metabolic processing
multiple interactions

EXP
ISO

HEPH protein affects the metabolism of Iron
[Zinc results in decreased expression of HEPH protein] which results in decreased uptake of Iron

PMID:16614402 PMID:17194590

NCBI chr X:95,499,042...95,618,091
Ensembl chr X:95,498,965...95,618,091

G

homeostatic iron regulator

increases uptake
affects abundance
increases abundance
affects response to substance
multiple interactions
decreases uptake
affects metabolic processing

ISO
EXP

HFE gene mutant form results in increased uptake of Iron
HFE gene polymorphism affects the abundance of Iron; HFE protein affects the abundance of Iron
HFE gene mutant form results in increased abundance of Iron; HFE gene polymorphism results in increased abundance of Iron
HFE protein affects the susceptibility to Iron
[HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [HFE protein binds to TFR2 protein] which affects the susceptibility to Iron; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron]
HFE protein results in decreased uptake of Iron
[HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron
HFE protein affects the metabolism of Iron

PMID:10085150 PMID:12393473 PMID:16793930 PMID:16823846 PMID:16841247 More...

NCBI chr13:23,886,017...23,894,837
Ensembl chr13:23,886,017...23,894,837

G

hypoxia inducible factor 1, alpha subunit

multiple interactions
decreases metabolic processing
increases response to substance
decreases expression

ISO
EXP

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Quercetin results in decreased abundance of Iron] which results in increased expression of HIF1A protein; Iron inhibits the reaction [galangin results in increased expression of HIF1A protein]; Iron inhibits the reaction [manganese chloride results in increased expression of HIF1A protein]; Iron inhibits the reaction [Nickel results in increased stability of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of and affects the localization of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of HIF1A protein]
HIF1A gene mutant form results in decreased metabolism of Iron
HIF1A protein results in increased susceptibility to Iron
Iron deficiency results in decreased expression of HIF1A mRNA

PMID:12393473 PMID:16629162 PMID:16787915 PMID:16877034 PMID:17364964 More...

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

hemojuvelin BMP co-receptor

affects metabolic processing

EXP

HJV protein affects the metabolism of Iron

NCBI chr 3:96,432,479...96,436,532
Ensembl chr 3:96,432,488...96,436,526

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2

decreases expression

ISO

Iron deficiency results in decreased expression of HMGCS2 mRNA

NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054

G

heme oxygenase 1

multiple interactions
increases metabolic processing
increases expression

ISO
EXP

[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; [Ethanol results in increased expression of HMOX1 protein] which results in increased abundance of Iron; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; [Particulate Matter results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Iron promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron]
HMOX1 protein results in increased metabolism of Iron
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of HMOX1 mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein]; leonurine promotes the reaction [Iron results in increased expression of HMOX1 protein]
Iron deficiency results in increased expression of HMOX1 mRNA; Iron results in increased expression of HMOX1 protein

PMID:12393473 PMID:15602829 PMID:16439612 PMID:16629162 PMID:19136476 More...

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

hematopoietic prostaglandin D synthase

increases expression

ISO

Iron deficiency results in increased expression of HPGDS mRNA

NCBI chr 6:65,094,019...65,121,960
Ensembl chr 6:65,094,277...65,121,892

G

Harvey rat sarcoma virus oncogene

multiple interactions
affects localization

ISO

HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]
Iron affects the localization of HRAS protein

NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918

G

heat shock factor binding protein 1-like 1

decreases expression

ISO

Iron deficiency results in decreased expression of HSBP1L1 mRNA

NCBI chr18:80,272,154...80,293,329
Ensembl chr18:80,272,973...80,290,317

G

heat shock protein 1A

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPA1A mRNA

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 1-like

multiple interactions

ISO

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA

NCBI chr17:35,191,679...35,198,204
Ensembl chr17:35,191,679...35,198,261

G

heat shock protein 8

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPA8 mRNA

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 9

multiple interactions

ISO

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA

NCBI chr18:35,070,467...35,087,404
Ensembl chr18:35,070,467...35,087,410

G

heat shock protein 1

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPB1 mRNA

NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417

G

heat shock 105kDa/110kDa protein 1

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPH1 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA

PMID:12393473 PMID:22198552

NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841

G

huntingtin

decreases uptake

EXP

HTT protein mutant form results in decreased uptake of Iron

NCBI chr 5:34,919,084...35,069,878
Ensembl chr 5:34,919,084...35,069,878

G

intercellular adhesion molecule 1

multiple interactions

ISO

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

isopentenyl-diphosphate delta isomerase

decreases expression

ISO

Iron deficiency results in decreased expression of IDI1 mRNA

NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487

G

interferon gamma

multiple interactions

ISO

Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]; Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein]

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

intraflagellar transport 172

increases expression

ISO

Iron deficiency results in increased expression of SLB mRNA

NCBI chr 5:31,410,623...31,448,458
Ensembl chr 5:31,410,621...31,448,460

G

insulin-like growth factor 1

multiple interactions

ISO

IGF1 protein inhibits the reaction [Carbon Tetrachloride results in increased abundance of Iron]

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

insulin-like growth factor binding protein 3

increases expression
multiple interactions

ISO

Iron deficiency results in increased expression of IGFBP3 mRNA
[Arsenic co-treated with Iron] results in decreased expression of IGFBP3 mRNA

PMID:16629162 PMID:31739468

NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923

G

inhibitor of kappaB kinase beta

multiple interactions

ISO

deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]

NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605

G

interleukin 12a

multiple interactions

ISO

Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]

NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880

G

interleukin 12b

multiple interactions

ISO

Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]

NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860

G

interleukin 18

multiple interactions

ISO

Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein]

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

G

interleukin 1 alpha

multiple interactions

ISO

[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of IL1A mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

multiple interactions
increases expression

ISO
EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B protein; leonurine inhibits the reaction [Iron results in increased expression of IL1B protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of IL1B protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein]
[Particulate Matter results in increased abundance of Iron] which results in increased secretion of IL1B protein

PMID:16958088 PMID:22198552 PMID:32007923 PMID:32828744 PMID:35247364

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions
increases secretion

ISO
EXP

[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of IL6 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of IL6 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL6 mRNA; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
[IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron
Iron results in increased secretion of IL6 protein
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]

PMID:16460831 PMID:20302851 PMID:22198552 PMID:26416317 PMID:32828744 More...

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

inositol hexaphosphate kinase 2

multiple interactions

ISO

[Arsenic co-treated with Iron] results in increased expression of IP6K2 mRNA

NCBI chr 9:108,660,928...108,683,532
Ensembl chr 9:108,660,995...108,683,536

G

IQ motif containing D

increases expression

ISO

Iron deficiency results in increased expression of IQCD mRNA

NCBI chr 5:120,724,829...120,745,185
Ensembl chr 5:120,727,081...120,745,183

G

iron responsive element binding protein 2

affects metabolic processing
increases activity
multiple interactions

EXP
ISO

IREB2 protein affects the metabolism of Iron
Iron deficiency results in increased activity of IREB2 protein
Clofibrate inhibits the reaction [Iron deficiency results in increased activity of IREB2 protein]

PMID:11969379 PMID:17194590

NCBI chr 9:54,769,942...54,819,812
Ensembl chr 9:54,771,073...54,819,814

G

interferon regulatory factor 8

decreases expression

ISO

Iron deficiency results in decreased expression of IRF8 mRNA

NCBI chr 8:121,463,097...121,483,433
Ensembl chr 8:121,463,097...121,483,433

G

integrin alpha 6

increases expression

ISO

Iron deficiency results in increased expression of ITGA6 mRNA

NCBI chr 2:71,617,236...71,688,761
Ensembl chr 2:71,575,960...71,688,760

G

integrin alpha M

increases expression
multiple interactions

ISO

Iron deficiency results in increased expression of ITGAM mRNA; Iron deficiency results in increased expression of ITGAM protein
Vitamin D promotes the reaction [Iron deficiency results in increased expression of ITGAM protein]

NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663

G

integrin beta 2

increases expression

ISO

Iron deficiency results in increased expression of ITGB2 mRNA

NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542

G

intelectin 1 (galactofuranose binding)

multiple interactions

EXP

ITLN1 protein binds to and results in increased uptake of Iron

NCBI chr 1:171,345,691...171,362,893
Ensembl chr 1:171,345,690...171,362,862

G

JAZF zinc finger 1

increases expression

ISO

Iron deficiency results in increased expression of JAZF1 mRNA

NCBI chr 6:52,745,050...53,045,613
Ensembl chr 6:52,745,782...53,045,616

G

immunoglobulin joining chain

increases expression

ISO

Iron deficiency results in increased expression of JCHAIN mRNA

NCBI chr 5:88,667,663...88,675,667
Ensembl chr 5:88,667,668...88,675,750

G

jun proto-oncogene

multiple interactions
increases expression

ISO

[Arsenic co-treated with Iron] results in increased expression of JUN mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA
Iron deficiency results in increased expression of JUN mRNA

PMID:12393473 PMID:20368581 PMID:31739468

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

potassium voltage-gated channel, Isk-related subfamily, gene 3

increases expression

ISO

Iron deficiency results in increased expression of KCNE3 mRNA

NCBI chr 7:99,825,714...99,834,076
Ensembl chr 7:99,825,709...99,834,076

G

lysine (K)-specific demethylase 3A

multiple interactions

ISO

[[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein

NCBI chr 6:71,565,954...71,609,963
Ensembl chr 6:71,565,956...71,609,974

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

ISO

Iron deficiency results in decreased expression of KIT mRNA

NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382

G

kelch domain containing 7B

increases expression

ISO

Iron deficiency results in increased expression of KLHDC7B mRNA

NCBI chr15:89,268,262...89,274,025
Ensembl chr15:89,269,120...89,273,070

G

laminin, gamma 2

increases expression

ISO

Iron deficiency results in increased expression of LAMC2 mRNA

NCBI chr 1:152,998,502...153,062,193
Ensembl chr 1:152,998,502...153,062,193

G

lysosomal-associated membrane protein family, member 5

decreases expression

ISO

Iron deficiency results in decreased expression of LAMP5 mRNA

NCBI chr 2:135,893,945...135,911,837
Ensembl chr 2:135,894,159...135,911,837

G

lipocalin 2

increases expression
affects metabolic processing

EXP

Iron results in increased expression of LCN2 mRNA; Iron results in increased expression of LCN2 protein
LCN2 protein affects the metabolism of Iron

PMID:17194590 PMID:17350462

NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264

G

ligase III, DNA, ATP-dependent

decreases activity

ISO

Iron results in decreased activity of LIG3 protein

NCBI chr11:82,671,977...82,695,100
Ensembl chr11:82,671,934...82,695,100

G

lysyl oxidase

multiple interactions

ISO

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA

NCBI chr18:52,649,132...52,662,939
Ensembl chr18:52,649,139...52,662,939

G

lysophosphatidic acid receptor 1

decreases expression

ISO

Iron deficiency results in decreased expression of LPAR1 mRNA

NCBI chr 4:58,435,252...58,554,601
Ensembl chr 4:58,435,255...58,553,898

G

leucine rich repeat containing 25

increases expression

ISO

Iron deficiency results in increased expression of LRRC25 mRNA

NCBI chr 8:71,068,810...71,073,501
Ensembl chr 8:71,068,805...71,074,133

G

lymphotoxin A

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of LTA mRNA

NCBI chr17:35,422,141...35,424,568
Ensembl chr17:35,422,141...35,424,327

G

lymphocyte antigen 75

decreases expression

ISO

Iron deficiency results in decreased expression of LY75 mRNA

NCBI chr 2:60,122,447...60,213,617
Ensembl chr 2:60,122,447...60,213,647

G

lysophospholipase 1

decreases expression

ISO

Iron deficiency results in decreased expression of LYPLA1 mRNA

NCBI chr 1:4,878,046...4,916,958
Ensembl chr 1:4,878,011...4,918,633

G

monoamine oxidase A

decreases expression

ISO

Iron deficiency results in decreased expression of MAOA mRNA

NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein; BECN1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; BECN1 protein affects the reaction [Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Hydrogen Peroxide inhibits the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of MAP1LC3B protein]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]

PMID:25301941 PMID:34826546

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

G

mitogen-activated protein kinase kinase 6

multiple interactions
increases phosphorylation

ISO

Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAP2K6 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]

NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348

G

mitogen-activated protein kinase kinase kinase 14

multiple interactions

ISO

MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]

NCBI chr11:103,110,590...103,158,227
Ensembl chr11:103,110,588...103,158,298

G

mitogen-activated protein kinase kinase kinase 7

multiple interactions
affects localization
increases activity

ISO

Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased activity of MAP3K7 protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein]
Iron affects the localization of MAP3K7 protein

NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

ISO
EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of MAPK1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK1 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]
[ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein

PMID:11306436 PMID:16728372 PMID:17172471 PMID:23100159 PMID:30914277 More...

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

ISO
EXP

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein; [teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK3 protein; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]
[Iron co-treated with Arsenic] results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein]
[ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein

PMID:11306436 PMID:16728372 PMID:17172471 PMID:23100159 PMID:30914277 More...

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

mitogen-activated protein kinase 8

multiple interactions

ISO

[teferrol results in increased abundance of Iron] which results in increased phosphorylation of MAPK8 protein

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

myristoylated alanine rich protein kinase C substrate

increases expression

ISO

Iron deficiency results in increased expression of MARCKS mRNA

NCBI chr10:37,009,239...37,014,922
Ensembl chr10:37,009,371...37,014,916

G

mast cell expressed membrane protein 1

increases expression

ISO

Iron deficiency results in increased expression of MCEMP1 mRNA

NCBI chr 8:3,715,754...3,718,916
Ensembl chr 8:3,715,754...3,719,259

G

mucolipin 1

multiple interactions
increases expression

EXP

[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA; [Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 protein]
Iron results in increased expression of MCOLN1 mRNA; Iron results in increased expression of MCOLN1 protein

NCBI chr 8:3,550,458...3,565,232
Ensembl chr 8:3,550,457...3,565,232

G

multiple C2 domains, transmembrane 1

increases expression

ISO

Iron deficiency results in increased expression of MCTP1 mRNA

NCBI chr13:76,530,481...77,181,403
Ensembl chr13:76,532,259...77,179,929

G

malic enzyme 1, NADP(+)-dependent, cytosolic

increases expression

ISO

Iron deficiency results in increased expression of ME1 mRNA

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

macrophage migration inhibitory factor (glycosylation-inhibiting factor)

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of MIF mRNA

NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074

G

myo-inositol oxygenase

affects binding

EXP

[MIOX protein binds to Iron] which binds to Inositol

NCBI chr15:89,218,676...89,221,210
Ensembl chr15:89,218,601...89,221,218

G

Mir17 host gene (non-protein coding)

decreases expression

ISO

Iron deficiency results in decreased expression of MIR17HG mRNA

NCBI chr14:115,281,822...115,284,160
Ensembl chr14:115,278,211...115,284,162

G

microRNA 196b

multiple interactions

ISO

[Air Pollutants, Occupational results in increased abundance of Iron] which results in increased expression of MIR196B mRNA

NCBI chr 6:52,207,061...52,207,145
Ensembl chr 6:52,207,061...52,207,145

G

matrix metallopeptidase 1b (interstitial collagenase)

multiple interactions

ISO

[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]

NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047

G

matrix metallopeptidase 9

multiple interactions

EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of MMP9 protein; Acetylcysteine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of MMP9 protein]; Deferoxamine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of MMP9 protein]

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

myeloperoxidase

increases activity
multiple interactions

ISO

Iron results in increased activity of MPO protein
[Hexachlorocyclohexane co-treated with Iron] results in increased activity of MPO protein

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

membrane-spanning 4-domains, subfamily A, member 6C

decreases expression

ISO

Iron deficiency results in decreased expression of MS4A6A mRNA

NCBI chr19:11,446,718...11,464,433
Ensembl chr19:11,446,730...11,459,556

G

membrane-spanning 4-domains, subfamily A, member 7

increases expression

ISO

Iron deficiency results in increased expression of MS4A7 mRNA

NCBI chr19:11,298,403...11,313,510
Ensembl chr19:11,298,403...11,313,510

G

metallothionein 1

multiple interactions
increases expression

EXP
ISO

ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]
Iron deficiency results in increased expression of MT1A; Iron deficiency results in increased expression of MT1A mRNA
[Zinc co-treated with Iron] results in increased expression of and affects the localization of MT1A protein; Iron results in increased expression of and affects the localization of MT1A protein

PMID:16629162 PMID:17241390 PMID:21852364 PMID:23776592 PMID:24089420

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 2

multiple interactions
increases expression
affects abundance

ISO
EXP

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA
Iron deficiency results in increased expression of MT2A mRNA
[Zinc co-treated with Iron] results in increased expression of and affects the localization of MT2A protein; Iron results in increased expression of and affects the localization of MT2A protein
Iron deficiency results in increased expression of MT2 mRNA
MT2A gene SNP affects the abundance of Iron

PMID:12393473 PMID:16629162 PMID:17241390 PMID:21328412 PMID:24089420

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

mevalonate (diphospho) decarboxylase

increases expression

ISO

Iron deficiency results in increased expression of MVD mRNA

NCBI chr 8:123,160,335...123,170,161
Ensembl chr 8:123,160,340...123,170,161

G

myelocytomatosis oncogene

multiple interactions

ISO

[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

N-myc downstream regulated gene 1

multiple interactions

ISO

[di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron] which results in increased expression of NDRG1 protein; NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron]

NCBI chr15:66,801,167...66,841,490
Ensembl chr15:66,801,167...66,841,489

G

NADH:ubiquinone oxidoreductase core subunit S1

affects expression

ISO

Iron affects the expression of NDUFS1 protein

NCBI chr 1:63,182,751...63,215,981
Ensembl chr 1:63,182,755...63,215,992

G

neural precursor cell expressed, developmentally down-regulated gene 9

increases expression

ISO

Iron deficiency results in increased expression of NEDD9 mRNA

NCBI chr13:41,463,392...41,640,836
Ensembl chr13:41,463,057...41,640,838

G

nei endonuclease VIII-like 1 (E. coli)

multiple interactions

ISO

Curcumin inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Edetic Acid inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Iron binds to and affects the folding of and results in decreased activity of NEIL1 protein; Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein]; Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein]

NCBI chr 9:57,050,072...57,055,973
Ensembl chr 9:57,050,084...57,055,589

G

nei like 2 (E. coli)

multiple interactions

ISO

Iron binds to and results in decreased activity of NEIL2 protein

NCBI chr14:63,419,888...63,431,604
Ensembl chr14:63,419,892...63,431,305

G

nuclear factor, erythroid derived 2, like 2

multiple interactions
increases activity
affects localization

EXP
ISO

NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]
Iron results in increased activity of NFE2L2 promoter
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of NFE2L2 mRNA; leonurine promotes the reaction [Iron affects the localization of NFE2L2 protein]
[Particulate Matter results in increased abundance of Iron] which affects the localization of NFE2L2 protein; [Particulate Matter results in increased abundance of Iron] which results in increased expression of NFE2L2 mRNA

PMID:20302851 PMID:21303654 PMID:21643505 PMID:26419736 PMID:35247364

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor I/B

multiple interactions

ISO

[Arsenic co-treated with Iron] results in decreased expression of NFIB mRNA

NCBI chr 4:82,208,410...82,424,988
Ensembl chr 4:82,208,410...82,623,987

G

nuclear factor, interleukin 3, regulated

increases expression

ISO

Iron deficiency results in increased expression of NFIL3 mRNA

NCBI chr13:53,121,245...53,136,914
Ensembl chr13:53,121,245...53,135,109

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein]; [Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of NFKBIA mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NFKBIA mRNA; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein]
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]

PMID:17172471 PMID:20302851 PMID:33285147

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

neuroglobin

decreases uptake

ISO

NGB protein results in decreased uptake of Iron

NCBI chr12:87,144,305...87,149,313
Ensembl chr12:87,144,305...87,149,313

G

NLR family, CARD domain containing 4

increases expression

ISO

Iron deficiency results in increased expression of NLRC4 mRNA

NCBI chr17:74,733,254...74,766,140
Ensembl chr17:74,732,433...74,766,137

G

N-myristoyltransferase 2

multiple interactions

ISO

[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of NMT2 mRNA

NCBI chr 2:3,285,249...3,329,914
Ensembl chr 2:3,285,249...3,329,914

G

nitric oxide synthase 2, inducible

multiple interactions

EXP
ISO

Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 mRNA]; Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 protein]
[Aluminum co-treated with Iron] results in increased expression of NOS2 protein; [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of NOS2 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NOS2 mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of NOS2 mRNA; [teferrol results in increased abundance of Iron] which results in increased expression of NOS2 mRNA

PMID:11461780 PMID:16728372 PMID:20302851 PMID:22198552 PMID:35307918

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

NPC intracellular cholesterol transporter 1

decreases abundance

EXP

NPC1 gene mutant form results in decreased abundance of Iron

NCBI chr18:12,322,751...12,369,851
Ensembl chr18:12,322,749...12,369,457

G

NAD(P)H dehydrogenase, quinone 1

increases reduction
multiple interactions
increases expression

ISO

NQO1 protein results in increased reduction of Iron
[Particulate Matter results in increased abundance of Iron] which results in increased expression of NQO1 mRNA
Iron results in increased expression of NQO1 protein
leonurine promotes the reaction [Iron results in increased expression of NQO1 protein]

PMID:17178108 PMID:26419736 PMID:35247364

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

occludin

multiple interactions

ISO

Iron inhibits the reaction [Lead results in decreased expression of OCLN mRNA]; Iron inhibits the reaction [Lead results in decreased expression of OCLN protein]

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

ornithine decarboxylase, structural 1

multiple interactions
increases activity

EXP

Iron affects the reaction [3-chloroperbenzoic acid results in increased activity of ODC1 protein]; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Hydrogen Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [mezerein results in increased activity of ODC1 protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ODC1 protein]
Iron results in increased activity of ODC1 protein

PMID:7653998 PMID:12065085 PMID:12067571 PMID:12504893

NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506

G

opsin 3

decreases expression

ISO

Iron deficiency results in decreased expression of OPN3 mRNA

NCBI chr 1:175,489,993...175,520,198
Ensembl chr 1:175,489,987...175,520,342

G

oxysterol binding protein-like 11

increases expression

ISO

Iron deficiency results in increased expression of OSBPL11 mRNA

NCBI chr16:33,005,441...33,063,682
Ensembl chr16:33,005,441...33,063,682

G

purinergic receptor P2X, ligand-gated ion channel, 7

increases expression

ISO

Iron deficiency results in increased expression of P2RX7 mRNA

NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495

G

procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide

increases expression

ISO

Iron deficiency results in increased expression of P4HA1 mRNA

NCBI chr10:59,159,019...59,209,126
Ensembl chr10:59,159,118...59,209,126

G

prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum)

multiple interactions

ISO

Iron inhibits the reaction [manganese chloride results in decreased activity of P4HTM protein]

NCBI chr 9:108,456,025...108,475,482
Ensembl chr 9:108,456,061...108,474,866

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions

ISO

[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; [ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]

PMID:30626086 PMID:31678598 PMID:34826546

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

polycomb group ring finger 5

increases expression

ISO

Iron deficiency results in increased expression of PCGF5 mRNA

NCBI chr19:36,325,729...36,438,370
Ensembl chr19:36,325,709...36,438,370

G

phosphoenolpyruvate carboxykinase 1, cytosolic

decreases expression

ISO

Iron deficiency results in decreased expression of PCK1 mRNA

NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066

G

proliferating cell nuclear antigen

increases expression
multiple interactions

ISO

Iron deficiency results in increased expression of PCNA mRNA
[taxifolin co-treated with [Iron-Dextran Complex results in increased abundance of Iron]] results in increased expression of PCNA protein

PMID:16629162 PMID:32828744

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

phosphatidylcholine transfer protein

decreases expression

ISO

Iron deficiency results in decreased expression of PCTP mRNA

NCBI chr11:89,873,370...89,893,720
Ensembl chr11:89,873,491...89,893,720

G

platelet derived growth factor, alpha

multiple interactions

ISO

Iron promotes the reaction [Asbestos, Amosite results in increased expression of PDGFA mRNA]

PMID:11306436 PMID:12475806

NCBI chr 5:138,961,761...138,986,336
Ensembl chr 5:138,961,769...138,983,125

G

pyruvate dehydrogenase kinase, isoenzyme 4

increases expression

ISO

Iron deficiency results in increased expression of PDK4 mRNA

NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

ISO

[cobaltous chloride results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA

NCBI chr 9:108,817,336...108,861,302
Ensembl chr 9:108,820,846...108,861,296

G

phosphatase, orphan 1

decreases expression

ISO

Iron deficiency results in decreased expression of PHOSPHO1 mRNA

NCBI chr11:95,715,326...95,722,966
Ensembl chr11:95,715,325...95,722,966

G

phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta

increases expression

ISO

Iron deficiency results in increased expression of PIK3C2B mRNA

NCBI chr 1:132,973,410...133,036,429
Ensembl chr 1:132,973,405...133,036,425

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

multiple interactions

ISO

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein; [Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein]

PMID:32828744 PMID:33580994

NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

ISO

Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]

NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725

G

proviral integration site 1

increases expression

ISO

Iron deficiency results in increased expression of PIM1 mRNA

NCBI chr17:29,709,759...29,715,085
Ensembl chr17:29,709,727...29,715,086

G

phosphatidylinositol-4-phosphate 5-kinase, type 1 beta

increases expression

ISO

Iron deficiency results in increased expression of PIP5K1B mRNA

NCBI chr19:24,272,158...24,533,236
Ensembl chr19:24,272,158...24,533,236

G

phospholipase A2, group IB, pancreas

increases expression

ISO

Iron deficiency results in increased expression of PLA2G1B mRNA

NCBI chr 5:115,604,201...115,612,781
Ensembl chr 5:115,604,321...115,612,781

G

phospholipase A2, group IVA (cytosolic, calcium-dependent)

decreases expression

ISO

Iron deficiency results in decreased expression of PLA2G4A mRNA

NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041

G

phospholipase A2, activating protein

decreases expression

ISO

Iron deficiency results in decreased expression of PLAA mRNA

NCBI chr 4:94,453,371...94,491,410
Ensembl chr 4:94,455,751...94,491,481

G

phospholipase D family member 4

decreases expression

ISO

Iron deficiency results in decreased expression of PLD4 mRNA

NCBI chr12:112,727,089...112,735,420
Ensembl chr12:112,727,089...112,735,424

G

phospholipid phosphatase 1

increases expression

ISO

Iron deficiency results in increased expression of PLPP1 mRNA

NCBI chr13:112,937,311...113,004,428
Ensembl chr13:112,937,326...113,004,428

G

phospholipid scramblase 1

decreases expression

ISO

Iron deficiency results in decreased expression of PLSCR1 mRNA

NCBI chr 9:92,132,265...92,154,034
Ensembl chr 9:92,131,803...92,154,331

G

peripheral myelin protein 22

increases expression
multiple interactions

ISO

Iron deficiency results in increased expression of PMP22 mRNA
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA

PMID:12393473 PMID:16629162 PMID:20368581

NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373

G

phosphomevalonate kinase

increases expression

ISO

Iron deficiency results in increased expression of PMVK mRNA

NCBI chr 3:89,361,848...89,376,321
Ensembl chr 3:89,361,848...89,376,320

G

pancreatic lipase

increases expression

ISO

Iron deficiency results in increased expression of PNLIP mRNA

NCBI chr19:58,658,797...58,670,231
Ensembl chr19:58,640,930...58,670,220

G

pancreatic lipase related protein 1

increases expression

ISO

Iron deficiency results in increased expression of PNLIPRP1 mRNA

NCBI chr19:58,717,319...58,732,601
Ensembl chr19:58,717,319...58,732,601

G

pancreatic lipase-related protein 2

decreases expression

ISO

Iron deficiency results in decreased expression of PNLIPRP2 mRNA

NCBI chr19:58,748,155...58,765,966
Ensembl chr19:58,748,151...58,765,966

G

protein O-glucosyltransferase 2

increases expression

ISO

Iron deficiency results in increased expression of POGLUT2 mRNA

NCBI chr 1:44,143,060...44,158,844
Ensembl chr 1:44,145,706...44,157,968

G

polymerase (DNA directed), beta

multiple interactions

ISO

Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein]

NCBI chr 8:23,118,135...23,143,482
Ensembl chr 8:23,118,142...23,143,451

G

polymerase (RNA) III (DNA directed) polypeptide E

multiple interactions

ISO

[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of POLR3E mRNA

NCBI chr 7:120,516,960...120,546,658
Ensembl chr 7:120,516,967...120,546,655

G

paraoxonase 1

multiple interactions

ISO

[Iron co-treated with Ascorbic Acid] results in decreased activity of PON1 protein; [Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein; Butylated Hydroxytoluene inhibits the reaction [[Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein]

NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946

G

cytochrome p450 oxidoreductase

multiple interactions

ISO

[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [Iron co-treated with POR protein] results in increased metabolism of Diquat; [Iron co-treated with POR protein] results in increased metabolism of Paraquat

NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180

G

peroxisome proliferator activated receptor gamma

increases expression

ISO

Iron deficiency results in increased expression of PPARG mRNA

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

protein phosphatase 1, regulatory subunit 16B

increases expression

ISO

Iron deficiency results in increased expression of PPP1R16B mRNA

NCBI chr 2:158,508,653...158,608,254
Ensembl chr 2:158,507,318...158,608,254

G

protein phosphatase 1, regulatory inhibitor subunit 1B

increases expression

ISO

Iron deficiency results in increased expression of PPP1R1B mRNA

NCBI chr11:98,239,232...98,248,622
Ensembl chr11:98,239,230...98,248,622

G

proteoglycan 3

decreases expression

ISO

Iron deficiency results in decreased expression of PRG3 mRNA

NCBI chr 2:84,818,540...84,826,903
Ensembl chr 2:84,818,559...84,824,230

G

protein kinase, AMP-activated, alpha 1 catalytic subunit

decreases expression

ISO

Iron deficiency results in decreased expression of PRKAA1 mRNA

NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380

G

prion protein

multiple interactions
decreases abundance

EXP

[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein; Edetic Acid inhibits the reaction [[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein]; Iron, Dietary inhibits the reaction [PRNP gene mutant form results in decreased abundance of Iron]

PMID:16595185 PMID:23478311

NCBI chr 2:131,751,848...131,780,356
Ensembl chr 2:131,751,848...131,780,349

G

proteinase 3

decreases expression

ISO

Iron deficiency results in decreased expression of PRTN3 mRNA

NCBI chr10:79,715,499...79,719,008
Ensembl chr10:79,710,310...79,719,008

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

ISO

[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of PTGS2 protein; leonurine inhibits the reaction [Iron results in increased expression of PTGS2 protein]
[Arsenic co-treated with Iron] results in increased expression of PTGS2 mRNA

PMID:20302851 PMID:31739468 PMID:35247364

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

parathyroid hormone-like peptide

multiple interactions

ISO

[Arsenic co-treated with Iron] results in increased expression of PTHLH mRNA

NCBI chr 6:147,153,607...147,165,511
Ensembl chr 6:147,153,599...147,165,681

G

pentraxin related gene

increases expression

ISO

Iron deficiency results in increased expression of PTX3 mRNA

NCBI chr 3:66,127,308...66,133,227
Ensembl chr 3:66,127,331...66,133,226

G

peroxidasin

multiple interactions

ISO

[Arsenic co-treated with Iron] results in decreased expression of PXDN mRNA

NCBI chr12:29,986,641...30,067,657
Ensembl chr12:29,987,607...30,067,657

G

RAB30, member RAS oncogene family

decreases expression

ISO

Iron deficiency results in decreased expression of RAB30 mRNA

NCBI chr 7:92,390,845...92,493,743
Ensembl chr 7:92,390,811...92,493,743

G

RAS, dexamethasone-induced 1

multiple interactions

ISO

Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]

NCBI chr11:59,854,007...59,855,770
Ensembl chr11:59,854,007...59,855,770

G

retinol binding protein 7, cellular

increases expression

ISO

Iron deficiency results in increased expression of RBP7 mRNA

NCBI chr 4:149,534,144...149,550,919
Ensembl chr 4:149,534,144...149,539,435

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions
affects localization

ISO

[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; U 0126 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]
[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; leonurine inhibits the reaction [Iron affects the localization of RELA protein]

PMID:33285147 PMID:33580994 PMID:35247364

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

avian reticuloendotheliosis viral (v-rel) oncogene related B

increases expression

ISO

Iron deficiency results in increased expression of RELB mRNA

NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363

G

resistin

increases expression

ISO

Iron deficiency results in increased expression of RETN mRNA

NCBI chr 8:3,705,770...3,709,818
Ensembl chr 8:3,705,770...3,710,110

G

regulator of G-protein signaling 1

increases expression

ISO

Iron deficiency results in increased expression of RGS1 mRNA

NCBI chr 1:144,120,407...144,124,862
Ensembl chr 1:144,118,034...144,124,980

G

regulator of G-protein signaling 2

increases expression

ISO

Iron deficiency results in increased expression of RGS2 mRNA

NCBI chr 1:143,875,076...143,879,887
Ensembl chr 1:143,875,076...143,879,899

G

rhodopsin

multiple interactions

EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA]

NCBI chr 6:115,903,741...115,916,999
Ensembl chr 6:115,908,709...115,916,997

G

ras homolog family member B

increases expression

ISO

Iron deficiency results in increased expression of RHOB mRNA

NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009

G

ribonuclease, RNase A family 4

increases expression

ISO

Iron deficiency results in increased expression of RNASE4 mRNA

NCBI chr14:51,328,534...51,343,608
Ensembl chr14:51,328,534...51,343,608

G

ropporin 1-like

decreases expression

ISO

Iron deficiency results in decreased expression of ROPN1L mRNA

NCBI chr15:31,441,356...31,453,835
Ensembl chr15:31,441,357...31,453,883

G

retinal pigment epithelium 65

multiple interactions

EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA]

NCBI chr 3:159,304,712...159,330,944
Ensembl chr 3:159,304,812...159,330,958

G

ribosomal protein L37

decreases expression

ISO

Iron results in decreased expression of RPL37 mRNA

NCBI chr15:5,146,127...5,148,626
Ensembl chr15:5,146,127...5,148,622

G

ribonucleotide reductase M2

multiple interactions

EXP

[Iron co-treated with Oxygen] binds to RRM2 protein

NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145

G

S100 calcium binding protein A9 (calgranulin B)

decreases expression

ISO

Iron deficiency results in decreased expression of S100A9 mRNA

NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028

G

stearoyl-Coenzyme A desaturase 2

increases expression
decreases expression

ISO

Iron deficiency results in increased expression of SCD2 mRNA
Iron deficiency results in decreased expression of SCD2 mRNA

PMID:16629162 PMID:19821111

NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303

G

sterol carrier protein 2, liver

decreases expression

ISO

Iron deficiency results in decreased expression of SCP2 mRNA

NCBI chr 4:107,901,027...108,002,168
Ensembl chr 4:107,901,036...108,002,195

G

selectin, endothelial cell

multiple interactions

ISO

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246

G

serine (or cysteine) peptidase inhibitor, clade B, member 8

increases expression

ISO

Iron deficiency results in increased expression of SERPINB8 mRNA

NCBI chr 1:107,517,668...107,536,708
Ensembl chr 1:107,517,736...107,538,214

G

sestrin 3

decreases expression

ISO

Iron deficiency results in decreased expression of SESN3 mRNA

NCBI chr 9:14,187,597...14,237,430
Ensembl chr 9:14,186,363...14,244,397

G

sirtuin 1

multiple interactions

ISO

[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; PARP1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in decreased expression of PARP1 protein]; SIRT1 protein affects the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

spindle and kinetochore associated complex subunit 1

increases expression

ISO

Iron deficiency results in increased expression of SKA1 mRNA

NCBI chr18:74,328,370...74,340,889
Ensembl chr18:74,328,370...74,340,889

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1

multiple interactions

EXP

[CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA

NCBI chr 1:74,414,318...74,429,974
Ensembl chr 1:74,414,354...74,425,221

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2

multiple interactions
decreases expression
increases expression
increases uptake
affects metabolic processing
decreases transport
decreases uptake
increases transport
affects abundance

ISO
EXP

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; cupric chloride inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein]; Dronabinol inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; ebselen inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; prolinedithiocarbamate inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]
Iron results in decreased expression of SLC11A2 protein
Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein
[Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein; [SLC11A2 protein mutant form results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; [Staurosporine results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC11A2 protein]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 protein]
SLC11A2 protein alternative form results in increased uptake of Iron; SLC11A2 protein results in increased uptake of Iron
SLC11A2 protein affects the metabolism of Iron
SLC11A2 gene mutant form results in decreased transport of Iron
SLC11A2 gene mutant form results in decreased uptake of Iron; SLC11A2 protein mutant form results in decreased uptake of Iron
SLC11A2 protein results in increased transport of Iron
Iron deficiency results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein
[Doxorubicin results in increased expression of SLC11A2 protein] which results in increased uptake of Iron; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of manganese chloride]; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of Manganese]; Manganese promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Metals promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]; SLC11A2 protein affects the reaction [Manganese results in increased transport of Iron]
Iron deficiency results in increased expression of SLC11A2 mRNA; Iron deficiency results in increased expression of SLC11A2 protein; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein
SLC11A2 gene SNP affects the abundance of Iron

PMID:11439223 PMID:12220667 PMID:12388109 PMID:12393473 PMID:15157939 More...

NCBI chr15:100,285,779...100,322,090
Ensembl chr15:100,285,779...100,322,953

G

solute carrier family 12, member 2

increases expression

ISO

Iron deficiency results in increased expression of SLC12A2 mRNA

NCBI chr18:58,011,505...58,079,893
Ensembl chr18:58,011,750...58,079,893

G

solute carrier family 23 (nucleobase transporters), member 2

increases expression

ISO

Iron deficiency results in increased expression of SLC23A2 mRNA

NCBI chr 2:131,894,416...131,987,287
Ensembl chr 2:131,894,416...131,987,028

G

solute carrier family 26, member 11

increases expression

ISO

Iron deficiency results in increased expression of SLC26A11 mRNA

NCBI chr11:119,246,328...119,271,902
Ensembl chr11:119,246,383...119,271,905

G

solute carrier family 2 (facilitated glucose transporter), member 5

decreases expression

ISO

Iron deficiency results in decreased expression of SLC2A5 mRNA

PMID:16629162 PMID:20368581

NCBI chr 4:150,203,801...150,228,625
Ensembl chr 4:150,203,740...150,228,626

G

solute carrier family 34 (sodium phosphate), member 2

decreases expression

ISO

Iron deficiency results in decreased expression of SLC34A2 mRNA

NCBI chr 5:53,206,695...53,229,006
Ensembl chr 5:53,195,423...53,229,006

G

solute carrier family 39 (zinc transporter), member 14

multiple interactions
increases uptake
increases expression
increases import

EXP

4,7-diphenylphenanthroline sulfonate inhibits the reaction [SLC39A14 protein results in increased uptake of Iron]; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 protein]
Iron results in increased expression of SLC39A14 mRNA; Iron results in increased expression of SLC39A14 protein
SLC39A14 protein results in increased import of Iron

PMID:16950869 PMID:22898811 PMID:24569067

NCBI chr14:70,540,916...70,588,873
Ensembl chr14:70,540,918...70,588,874

G

solute carrier family 39 (metal ion transporter), member 8

increases import
multiple interactions

ISO
EXP

SLC39A8 protein results in increased import of Iron
Iron inhibits the reaction [SLC39A8 protein results in increased uptake of Zinc]; Protons affects the reaction [SLC39A8 protein results in increased import of Iron]
Cobalt inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Iron inhibits the reaction [SLC39A8 protein results in increased import of Zinc]; Iron results in increased expression of and affects the localization of SLC39A8 protein; Manganese inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Zinc inhibits the reaction [SLC39A8 protein results in increased import of Iron]

PMID:22898811 PMID:27956349

NCBI chr 3:135,522,644...135,594,333
Ensembl chr 3:135,531,040...135,594,333

G

solute carrier family 40 (iron-regulated transporter), member 1

decreases expression
affects metabolic processing
multiple interactions
increases expression
decreases export
increases export

EXP
ISO

Iron results in decreased expression of SLC40A1 protein
SLC40A1 protein affects the metabolism of Iron
[HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 mRNA]; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 protein]; NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron]
Iron deficiency results in increased expression of SLC40A1 mRNA
SLC40A1 protein mutant form results in decreased export of Iron
SLC40A1 protein mutant form results in increased export of Iron; SLC40A1 protein results in increased export of Iron
Iron deficiency results in increased expression of SLC40A1 mRNA; Iron results in increased expression of SLC40A1 mRNA
[CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]; Iron inhibits the reaction [SLC40A1 protein results in increased export of Manganese]

PMID:16457665 PMID:16565419 PMID:16648237 PMID:17018382 PMID:17194590 More...

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

solute carrier family 6 (neurotransmitter transporter, GABA), member 1

multiple interactions
decreases expression
increases expression

ISO

[Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 protein; [Iron deficiency co-treated with manganese chloride] results in increased expression of SLC6A1 mRNA
Iron deficiency results in decreased expression of SLC6A1 protein
Iron deficiency results in increased expression of SLC6A1 mRNA

NCBI chr 6:114,259,735...114,294,491
Ensembl chr 6:114,259,596...114,294,493

G

solute carrier family 6 (neurotransmitter transporter, dopamine), member 3

multiple interactions

ISO

[manganese chloride co-treated with Iron deficiency] results in decreased expression of SLC6A3 protein

NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791

G

secretory leukocyte peptidase inhibitor

decreases expression

ISO

Iron deficiency results in decreased expression of SLPI mRNA

NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015

G

small integral membrane protein 3

increases expression

ISO

Iron deficiency results in increased expression of SMIM3 mRNA

NCBI chr18:60,607,263...60,635,055
Ensembl chr18:60,607,263...60,635,059

G

small nuclear RNA activating complex, polypeptide 1

increases expression

ISO

Iron deficiency results in increased expression of SNAPC1 mRNA

NCBI chr12:74,011,271...74,035,836
Ensembl chr12:74,011,255...74,035,740

G

synuclein, alpha

multiple interactions
increases response to substance
affects localization

ISO
EXP

Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Iron]
Iron affects the localization of SNCA protein
EUK-189 results in decreased susceptibility to [Iron co-treated with Paraquat co-treated with SNCA gene mutant form]

PMID:12401952 PMID:14535945 PMID:21039522 PMID:27324791

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

superoxide dismutase 1, soluble

multiple interactions
affects abundance

ISO
EXP

SOD1 protein inhibits the reaction [Asbestos, Crocidolite results in increased uptake of Iron]
[Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]
SOD1 protein affects the abundance of Iron
[Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD1 protein]

PMID:16272461 PMID:17194920 PMID:19482077 PMID:22534743

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

affects abundance
multiple interactions

ISO
EXP

SOD2 protein polymorphism affects the abundance of Iron
Iron results in decreased expression of and results in decreased activity of SOD2 protein
Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]; SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]
[Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD2 protein]

PMID:18760346 PMID:19063909 PMID:22534743

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

sorbitol dehydrogenase

affects abundance

ISO

SORD protein affects the abundance of Iron

NCBI chr 2:122,065,320...122,095,818
Ensembl chr 2:122,065,230...122,095,821

G

sortilin 1

increases expression

ISO

Iron deficiency results in increased expression of SORT1 mRNA

NCBI chr 3:108,191,272...108,268,835
Ensembl chr 3:108,191,398...108,268,827

G

SRY (sex determining region Y)-box 9

increases expression

ISO

Iron deficiency results in increased expression of SOX9 mRNA

NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586

G

trans-acting transcription factor 1

multiple interactions

ISO

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]

NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839

G

trans-acting transcription factor 6

increases expression

ISO

Iron deficiency results in increased expression of SP6 mRNA

NCBI chr11:96,904,395...96,915,565
Ensembl chr11:96,904,220...96,915,560

G

sepiapterin reductase

increases expression

ISO

Iron deficiency results in increased expression of SPR mRNA

NCBI chr 6:85,110,662...85,114,746
Ensembl chr 6:85,107,158...85,114,748

G

sequestosome 1

multiple interactions

ISO

[Arsenic co-treated with Iron] results in increased expression of SQSTM1 mRNA; [Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of SQSTM1 protein]

PMID:25301941 PMID:31739468

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

Rous sarcoma oncogene

multiple interactions

ISO

Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of SRC protein]

NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782

G

signal sequence receptor, alpha

multiple interactions

ISO

[Arsenic co-treated with Iron] results in decreased expression of SSR1 mRNA

NCBI chr13:38,155,377...38,178,184
Ensembl chr13:38,150,581...38,178,193

G

six transmembrane epithelial antigen of prostate 2

increases reduction
increases uptake

EXP

STEAP2 protein results in increased reduction of Iron
STEAP2 protein results in increased uptake of Iron

NCBI chr 5:5,714,829...5,744,649
Ensembl chr 5:5,714,829...5,744,578

G

STEAP family member 3

affects metabolic processing
increases uptake
increases reduction

EXP

STEAP3 protein affects the metabolism of Iron
STEAP3 protein results in increased uptake of Iron
STEAP3 protein results in increased reduction of Iron

PMID:16609065 PMID:17194590

NCBI chr 1:120,154,137...120,198,810
Ensembl chr 1:120,118,487...120,200,435

G

STEAP family member 4

increases uptake
increases reduction

EXP

STEAP4 protein results in increased uptake of Iron
STEAP4 protein results in increased reduction of Iron

NCBI chr 5:8,010,472...8,032,213
Ensembl chr 5:8,010,457...8,032,213

G

serine/threonine kinase 11

multiple interactions

ISO

STK11 protein affects the reaction [resveratrol results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]]

NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516

G

sulfatase 2

increases expression

ISO

Iron deficiency results in increased expression of SULF2 mRNA

NCBI chr 2:165,915,819...165,997,603
Ensembl chr 2:165,915,009...165,997,583

G

TLR adaptor interacting with endolysosomal SLC15A4

decreases expression

ISO

Iron deficiency results in decreased expression of TASL mRNA

NCBI chr X:84,820,445...84,935,105
Ensembl chr X:84,913,960...84,935,105

G

telomerase reverse transcriptase

increases activity

ISO

Iron results in increased activity of TERT protein

NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962

G

testin LIM domain protein

increases expression

ISO

Iron deficiency results in increased expression of TES mRNA

NCBI chr 6:17,065,148...17,105,824
Ensembl chr 6:17,065,148...17,105,827

G

trefoil factor 1

increases expression

ISO

Iron deficiency results in increased expression of TFF1 mRNA

NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251

G

transferrin receptor 2

multiple interactions
affects response to substance
increases uptake
affects metabolic processing
decreases expression

ISO
EXP

[HFE protein binds to TFR2 protein] which affects the susceptibility to Iron
[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of TFR2 protein]
TFR2 protein affects the susceptibility to Iron
TFR2 protein mutant form results in increased uptake of Iron
TFR2 protein affects the metabolism of Iron
Iron deficiency results in decreased expression of TFR2 protein

PMID:16893896 PMID:16935854 PMID:17018382 PMID:17194590 PMID:17241880 More...

NCBI chr 5:137,568,127...137,586,344
Ensembl chr 5:137,568,102...137,585,743

G

transferrin receptor

multiple interactions
affects binding
increases expression
increases uptake
affects metabolic processing
affects expression
decreases expression

ISO
EXP

[Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [GGTI 298 results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein; [TFRC protein results in increased uptake of Iron] which results in increased abundance of Lipid Peroxides; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; Deferiprone inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein]; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]
[Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein
Iron results in increased expression of TFRC protein
[CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [Iron co-treated with Ethanol] results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC protein; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of TFRC mRNA]
TFRC protein affects the metabolism of Iron
Iron affects the expression of TFRC mRNA; Iron affects the expression of TFRC protein
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC protein; Clofibrate inhibits the reaction [Iron deficiency results in increased expression of TFRC mRNA]
Iron deficiency results in increased expression of TFRC mRNA; Iron deficiency results in increased expression of TFRC protein
Iron results in decreased expression of TFRC mRNA
Iron deficiency results in increased expression of TFRC mRNA; Iron results in increased expression of TFRC mRNA

PMID:10085150 PMID:11068183 PMID:11969379 PMID:12393473 PMID:16428268 More...

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

G

transforming growth factor, beta 1

multiple interactions

ISO

Iron promotes the reaction [Asbestos, Amosite results in increased expression of TGFB1 mRNA]

PMID:11306436 PMID:12475806

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta receptor I

multiple interactions

ISO

[Arsenic co-treated with Iron] results in increased expression of TGFBR1 mRNA

NCBI chr 4:47,353,258...47,414,926
Ensembl chr 4:47,353,222...47,414,931

G

TGFB-induced factor homeobox 1

increases expression

ISO

Iron deficiency results in increased expression of TGIF1 mRNA

NCBI chr17:71,151,200...71,160,527
Ensembl chr17:71,151,200...71,160,541

G

transmembrane protein 154

increases expression

ISO

Iron deficiency results in increased expression of TMEM154 mRNA

NCBI chr 3:84,573,499...84,611,882
Ensembl chr 3:84,573,499...84,611,882

G

transmembrane protein 252

increases expression

ISO

Iron deficiency results in increased expression of TMEM252 mRNA

NCBI chr19:24,651,372...24,657,025
Ensembl chr19:24,651,372...24,659,597

G

transmembrane protein 45b

decreases expression

ISO

Iron deficiency results in decreased expression of TMEM45B mRNA

NCBI chr 9:31,336,445...31,375,534
Ensembl chr 9:31,337,492...31,375,758

G

transmembrane protein 86A

increases expression

ISO

Iron deficiency results in increased expression of TMEM86A mRNA

NCBI chr 7:46,700,388...46,704,524
Ensembl chr 7:46,700,349...46,704,525

G

transmembrane serine protease 6

affects abundance

ISO

TMPRSS6 gene SNP affects the abundance of Iron

PMID:19820698 PMID:19820699

NCBI chr15:78,323,867...78,352,848
Ensembl chr15:78,323,867...78,352,834

G

tumor necrosis factor

multiple interactions
decreases abundance
increases secretion
increases expression
increases uptake

ISO
EXP

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron]
TNF protein results in decreased abundance of Iron
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased secretion of TNF protein]; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of TNF protein; Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; leonurine inhibits the reaction [Iron results in increased expression of TNF protein]; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; TNF protein affects the transport of and results in decreased abundance of Iron; U 0126 inhibits the reaction [Iron results in increased secretion of TNF protein]
Iron results in increased expression of TNF mRNA; Iron results in increased expression of TNF protein
TNF protein results in increased uptake of Iron
[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]

PMID:10865941 PMID:12633744 PMID:16566752 PMID:16793930 PMID:16890145 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor (ligand) superfamily, member 10

increases expression

ISO

Iron deficiency results in increased expression of TNFSF10 mRNA

NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576

G

tumor necrosis factor (ligand) superfamily, member 11

multiple interactions

EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNFSF11; Acetylcysteine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNFSF11]; Deferoxamine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNFSF11]

NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483

G

tubulin polymerization-promoting protein family member 3

increases expression

ISO

Iron deficiency results in increased expression of TPPP3 mRNA

NCBI chr 8:106,194,124...106,198,189
Ensembl chr 8:106,194,125...106,198,158

G

triggering receptor expressed on myeloid cells-like 2

increases expression

ISO

Iron deficiency results in increased expression of TREML2 mRNA

NCBI chr17:48,606,419...48,619,562
Ensembl chr17:48,606,526...48,619,561

G

transferrin

multiple interactions
affects binding
increases uptake
increases expression
affects metabolic processing

ISO
EXP

[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Iron binds to TF protein] which results in decreased uptake of Iron; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Iron; ammonium ferric sulfate promotes the reaction [TF protein results in increased uptake of Iron]; cobaltous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; cuprous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron]; ferric chloride promotes the reaction [TF protein results in increased uptake of Iron]; ferrous sulfate promotes the reaction [TF protein results in increased uptake of Iron]; gallium nitrate promotes the reaction [TF protein results in increased uptake of Iron]; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and affects the transport of Iron; zinc chloride inhibits the reaction [TF protein results in increased uptake of Iron]
[Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein; CP protein binds to [TF protein binds to Iron]; Iron binds to TF protein; TF protein binds to Iron
[Iron deficiency co-treated with Manganese] results in increased expression of TF protein; [Melatonin results in increased expression of TF protein] which affects the abundance of Iron; [S-Adenosylmethionine results in increased expression of TF protein] which affects the abundance of Iron; Copper deficiency results in decreased expression of [Iron binds to TF protein]
Iron deficiency results in increased expression of TF protein
TRF protein affects the metabolism of Iron

PMID:2039817 PMID:2308257 PMID:8782865 PMID:11193083 PMID:11335103 More...

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

tripartite motif-containing 27

increases expression

ISO

Iron deficiency results in increased expression of TRIM27 mRNA

NCBI chr13:21,363,570...21,378,893
Ensembl chr13:21,363,615...21,378,894

G

transient receptor potential cation channel, subfamily C, member 6

increases uptake

EXP

TRPC6 protein results in increased uptake of Iron

NCBI chr 9:8,543,868...8,680,753
Ensembl chr 9:8,544,143...8,680,742

G

teashirt zinc finger family member 1

increases expression

ISO

Iron deficiency results in increased expression of TSHZ1 mRNA

NCBI chr18:84,029,752...84,105,833
Ensembl chr18:84,029,752...84,105,831

G

teashirt zinc finger family member 3

increases expression

ISO

Iron deficiency results in increased expression of TSHZ3 mRNA

NCBI chr 7:36,397,543...36,472,978
Ensembl chr 7:36,397,543...36,472,978

G

thioredoxin 2

multiple interactions

ISO

[3-aminopyridine-2-carboxaldehyde thiosemicarbazone binds to Iron] which results in increased oxidation of TXN2 protein

NCBI chr15:77,799,251...77,813,194
Ensembl chr15:77,799,247...77,813,206

G

thioredoxin interacting protein

multiple interactions

EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNIP protein

NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199

G

thioredoxin reductase 1

multiple interactions

EXP

[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of TXNRD1 mRNA; [Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TXNRD1 protein

NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546

G

ubiquitin-conjugating enzyme E2E 1

decreases expression

ISO

Iron deficiency results in decreased expression of UBE2E1 mRNA

NCBI chr14:4,137,852...4,186,967
Ensembl chr14:4,137,837...4,186,974

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

multiple interactions

ISO

[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of UGT1A6 mRNA

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

UDP glucuronosyltransferase 2 family, polypeptide B1

decreases expression

ISO

Iron deficiency results in decreased expression of UGT2B17 mRNA

NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389

G

uroporphyrinogen decarboxylase

decreases activity
multiple interactions

ISO

Iron results in decreased activity of UROD protein
Iron inhibits the reaction [Ethinyl Estradiol results in increased activity of UROD protein]

PMID:3945969 PMID:12030801

NCBI chr 4:116,847,161...116,851,561
Ensembl chr 4:116,847,162...116,851,610

G

vascular cell adhesion molecule 1

multiple interactions

ISO

[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

vitamin D (1,25-dihydroxyvitamin D3) receptor

increases expression

ISO

Iron deficiency results in increased expression of VDR mRNA

NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511

G

V-set and immunoglobulin domain containing 10 like

decreases expression

ISO

Iron deficiency results in decreased expression of VSIG10L mRNA

NCBI chr 7:43,112,460...43,121,443
Ensembl chr 7:43,112,575...43,121,443

G

WD repeat domain, phosphoinositide interacting 1

increases expression

ISO

Iron deficiency results in increased expression of WIPI1 mRNA

NCBI chr11:109,464,347...109,502,215
Ensembl chr11:109,464,157...109,502,793

G

zinc finger protein 503

increases expression

ISO

Iron deficiency results in increased expression of ZFP503 mRNA

NCBI chr14:22,034,030...22,039,669
Ensembl chr14:22,034,027...22,039,669

iron(2+) sulfate (anhydrous)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family F member 1

increases expression

ISO

ferrous sulfate results in increased expression of ABCF1 mRNA

NCBI chr17:36,267,711...36,280,642
Ensembl chr17:36,267,711...36,280,653

G

aconitase 1

multiple interactions

ISO

[nickel chloride results in increased activity of ACO1 protein] inhibits the reaction [ferrous sulfate results in increased expression of FTL protein]

NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338

G

actin alpha 2, smooth muscle, aorta

multiple interactions

ISO

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of ACTA2 protein

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

G

thymoma viral proto-oncogene 1

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

amyloid beta precursor protein

multiple interactions

ISO

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

ATPase, Ca++ transporting, cardiac muscle, fast twitch 1

multiple interactions

ISO

[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein; Butylated Hydroxytoluene inhibits the reaction [[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein]; dicarbine inhibits the reaction [[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein]

NCBI chr 7:126,045,032...126,062,245
Ensembl chr 7:126,045,030...126,062,280

G

BCL2-associated agonist of cell death

decreases expression

ISO

ferrous sulfate results in decreased expression of BAD mRNA

NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267

G

BCL2-associated X protein

increases expression
multiple interactions

ISO

ferrous sulfate results in increased expression of BAX protein
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

decreases expression
increases expression
multiple interactions

ISO

ferrous sulfate results in decreased expression of BCL2 protein
ferrous sulfate results in increased expression of BCL2 mRNA
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in decreased expression of BCL2 protein]

PMID:28583816 PMID:33554279

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

B cell leukemia/lymphoma 2 related protein A1b

increases expression

ISO

ferrous sulfate results in increased expression of BCL2A1 mRNA

NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880

G

caspase 3

increases cleavage
decreases activity
multiple interactions

ISO

ferrous sulfate results in increased cleavage of CASP3 protein
ferrous sulfate results in decreased activity of CASP3 protein
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA]
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased cleavage of CASP3 protein]

PMID:17879260 PMID:28583816 PMID:33554279

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 7

multiple interactions

ISO

[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA]

NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776

G

catalase

multiple interactions

EXP

CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased degradation of Hyaluronic Acid]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein]

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

caveolin 1, caveolae protein

affects localization

ISO

ferrous sulfate affects the localization of CAV1 protein

NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451

G

C-C motif chemokine ligand 17

decreases expression

ISO

ferrous sulfate results in decreased expression of CCL17 mRNA

NCBI chr 8:95,535,996...95,538,666
Ensembl chr 8:95,537,081...95,538,664

G

C-C motif chemokine ligand 19

decreases expression

ISO

ferrous sulfate results in decreased expression of CCL19 mRNA

NCBI chr 4:42,754,525...42,756,558
Ensembl chr 4:42,754,525...42,756,577

G

C-C motif chemokine ligand 20

increases expression

ISO

ferrous sulfate results in increased expression of CCL20 mRNA

PMID:19428942 PMID:21540303

NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888

G

C-C motif chemokine ligand 21 (serine)

decreases expression

ISO

ferrous sulfate results in decreased expression of CCL21 mRNA

NCBI chr 4:42,772,860...42,773,991
Ensembl chr 4:42,772,860...42,773,993

G

C-C motif chemokine ligand 24

decreases expression

ISO

ferrous sulfate results in decreased expression of CCL24 mRNA

NCBI chr 5:135,598,789...135,601,977
Ensembl chr 5:135,598,791...135,601,903

G

C-C motif chemokine ligand 6

decreases expression

ISO

ferrous sulfate results in decreased expression of CCL15 mRNA

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

C-C motif chemokine receptor 6

decreases expression

ISO

ferrous sulfate results in decreased expression of CCR6 mRNA

NCBI chr17:8,454,875...8,477,353
Ensembl chr17:8,454,875...8,475,973

G

C-C motif chemokine receptor 7

decreases expression

ISO

ferrous sulfate results in decreased expression of CCR7 mRNA

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

C-C motif chemokine receptor 8

decreases expression

ISO

ferrous sulfate results in decreased expression of CCR8 mRNA

NCBI chr 9:119,921,199...119,923,972
Ensembl chr 9:119,921,180...119,923,972

G

CD44 antigen

multiple interactions

EXP

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

cyclin dependent kinase inhibitor 1A

increases expression

ISO

ferrous sulfate results in increased expression of CDKN1A mRNA

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

CCAAT/enhancer binding protein beta

increases expression

ISO

ferrous sulfate results in increased expression of CEBPB mRNA

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

G

conserved helix-loop-helix ubiquitous kinase

multiple interactions

ISO

deferiprone inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]

NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919

G

C-reactive protein, pentraxin-related

decreases expression

ISO

ferrous sulfate results in decreased expression of CRP mRNA; ferrous sulfate results in decreased expression of CRP protein

PMID:17119383 PMID:19428942

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

colony stimulating factor 2 (granulocyte-macrophage)

increases expression

ISO

ferrous sulfate results in increased expression of CSF2 mRNA

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

C-X-C motif chemokine ligand 10

increases expression

ISO

ferrous sulfate results in increased expression of CXCL10 mRNA

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

chemokine (C-X-C motif) ligand 11

increases expression

ISO

ferrous sulfate results in increased expression of CXCL11 mRNA

NCBI chr 5:92,507,403...92,511,155
Ensembl chr 5:92,507,403...92,513,344

G

C-X-C motif chemokine ligand 13

decreases expression

ISO

ferrous sulfate results in decreased expression of CXCL13 mRNA

NCBI chr 5:96,104,785...96,108,927
Ensembl chr 5:96,104,810...96,108,927

G

C-X-C motif chemokine ligand 14

decreases expression

ISO

ferrous sulfate results in decreased expression of CXCL14 mRNA

NCBI chr13:56,436,456...56,444,624
Ensembl chr13:56,436,456...56,444,364

G

C-X-C motif chemokine ligand 15

multiple interactions
increases expression

ISO

ferrous sulfate inhibits the reaction [nickel sulfate results in increased expression of CXCL8 protein]; N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [ferrous sulfate results in increased expression of CXCL8 mRNA]

PMID:15081272 PMID:19428942 PMID:21540303

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 2

increases expression

ISO

ferrous sulfate results in increased expression of CXCL2 mRNA

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine receptor 2

decreases expression

ISO

ferrous sulfate results in decreased expression of CXCR2 mRNA

NCBI chr 1:74,193,153...74,200,405
Ensembl chr 1:74,193,150...74,200,405

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

EXP

ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; ferrous sulfate inhibits the reaction [picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

DnaJ heat shock protein family (Hsp40) member B1

decreases response to substance

ISO

DNAJB1 protein results in decreased susceptibility to ferrous sulfate

NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282

G

egl-9 family hypoxia-inducible factor 1

increases activity

ISO

ferrous sulfate results in increased activity of EGLN1 protein

NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063

G

early growth response 1

decreases expression

ISO

ferrous sulfate results in decreased expression of EGR1 mRNA

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

endothelial PAS domain protein 1

multiple interactions

ISO

ferrous sulfate inhibits the reaction [galangin results in increased expression of EPAS1 protein]; ferrous sulfate inhibits the reaction [Quercetin results in increased expression of EPAS1 protein]

NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]; ferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein]

NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542

G

coagulation factor X

decreases activity

ISO

ferrous sulfate results in decreased activity of F10 protein

NCBI chr 8:13,087,308...13,106,676
Ensembl chr 8:13,087,308...13,106,676

G

coagulation factor II

decreases activity

ISO

ferrous sulfate results in decreased activity of F2 protein

NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759

G

ferritin light polypeptide 1

multiple interactions
increases expression

ISO

[nickel chloride results in increased activity of ACO1 protein] inhibits the reaction [ferrous sulfate results in increased expression of FTL protein]
ferrous sulfate results in increased expression of FTL1 protein

PMID:16039939 PMID:28993186

NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
decreases expression

ISO

ferrous sulfate promotes the reaction [SNCA protein results in decreased expression of GCLC protein]
ferrous sulfate results in decreased expression of GCLC protein

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glial cell line derived neurotrophic factor

decreases response to substance

EXP

GDNF protein results in decreased susceptibility to ferrous sulfate

NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056

G

glial fibrillary acidic protein

multiple interactions

ISO

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

glutathione peroxidase 1

increases expression
multiple interactions

ISO

ferrous sulfate results in increased expression of GPX1 protein
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of GPX1 protein]

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

glycogen synthase kinase 3 beta

increases phosphorylation

ISO

ferrous sulfate results in increased phosphorylation of GSK3B protein

NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446

G

H2A.X variant histone

increases expression
multiple interactions

ISO

ferrous sulfate results in increased expression of H2AX protein
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of H2AX protein]

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

ISO

ferrous sulfate inhibits the reaction [Chromium results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Cobalt results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [galangin results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Nickel results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Quercetin results in increased expression of HIF1A protein]

PMID:16386771 PMID:17973296

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

heme oxygenase 1

multiple interactions
increases expression

ISO

ferrous sulfate inhibits the reaction [2,2'-Dipyridyl analog inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [2,2'-Dipyridyl analog inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [sulforaphane results in increased expression of HMOX1 mRNA]]
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of HMOX1 protein]

PMID:20934533 PMID:26945724 PMID:28583816

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

Harvey rat sarcoma virus oncogene

affects localization
multiple interactions

ISO

ferrous sulfate affects the localization of HRAS protein
ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]

NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918

G

heat shock protein 90, alpha (cytosolic), class A member 1

multiple interactions

ISO

ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]

NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162

G

interferon alpha 2

decreases expression

ISO

ferrous sulfate results in decreased expression of IFNA2 mRNA

NCBI chr 4:88,601,444...88,602,016
Ensembl chr 4:88,601,118...88,602,149

G

inhibitor of kappaB kinase beta

multiple interactions

ISO

Deferiprone inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]

NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605

G

interleukin 10 receptor, beta

decreases expression

ISO

ferrous sulfate results in decreased expression of IL10RB mRNA

NCBI chr16:91,203,166...91,222,718
Ensembl chr16:91,203,052...91,222,722

G

interleukin 1 beta

multiple interactions
increases expression

EXP
ISO

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]
ferrous sulfate results in increased expression of IL1B protein
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of IL1B protein]

PMID:23692848 PMID:28583816

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 1 receptor antagonist

increases expression

ISO

ferrous sulfate results in increased expression of IL1RN mRNA

NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506

G

interleukin 36 receptor antagonist

decreases expression

ISO

ferrous sulfate results in decreased expression of IL36RN mRNA

NCBI chr 2:24,166,966...24,172,444
Ensembl chr 2:24,166,966...24,173,438

G

interleukin 4

increases expression

ISO

ferrous sulfate results in increased expression of IL4 protein

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

G

interleukin 6

decreases expression

ISO

ferrous sulfate results in decreased expression of IL6 protein

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

jun proto-oncogene

increases expression

ISO

ferrous sulfate results in increased expression of JUN mRNA

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

kallikrein 1

decreases activity

ISO

ferrous sulfate results in decreased activity of KLK1 protein

NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042

G

leptin

increases expression

ISO

ferrous sulfate results in increased expression of LEP mRNA

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

lymphotoxin A

increases expression
decreases expression

ISO

ferrous sulfate results in increased expression of LTA mRNA
ferrous sulfate results in decreased expression of LTA mRNA

PMID:19428942 PMID:21540303

NCBI chr17:35,422,141...35,424,568
Ensembl chr17:35,422,141...35,424,327

G

mitogen-activated protein kinase kinase 6

multiple interactions
increases phosphorylation

ISO

ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; Filipin inhibits the reaction [ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAP2K6 protein]

NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348

G

mitogen-activated protein kinase kinase kinase 14

multiple interactions

ISO

MAP3K14 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]

NCBI chr11:103,110,590...103,158,227
Ensembl chr11:103,110,588...103,158,298

G

mitogen-activated protein kinase kinase kinase 7

affects localization
increases activity
multiple interactions

ISO

ferrous sulfate affects the localization of MAP3K7 protein
ferrous sulfate results in increased activity of MAP3K7 protein
ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; Filipin inhibits the reaction [ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of MAP3K7 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]

NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]

PMID:17172471 PMID:19608791

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]

PMID:17172471 PMID:19608791

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

microtubule-associated protein tau

multiple interactions

ISO

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

microRNA 146

multiple interactions

ISO

[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; Resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]

NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288

G

matrix metallopeptidase 13

multiple interactions
increases expression

EXP
ISO

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]
Diltiazem promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]; Nimodipine promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]; Verapamil promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]

PMID:23692848 PMID:27095094

NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331

G

metallothionein 1

multiple interactions
increases expression

ISO

[Zinc Sulfate co-treated with ferrous sulfate] results in increased expression of and affects the localization of MT1A protein; ferrous sulfate results in increased expression of and affects the localization of MT1A protein
ferrous sulfate results in increased expression of MT1A mRNA

PMID:17241390 PMID:19679144

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 2

multiple interactions

ISO

[Zinc Sulfate co-treated with ferrous sulfate] results in increased expression of and affects the localization of MT2A protein; ferrous sulfate results in increased expression of and affects the localization of MT2A protein

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

myeloblastosis oncogene

multiple interactions

ISO

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MYB protein

NCBI chr10:21,000,829...21,036,883
Ensembl chr10:21,000,834...21,036,883

G

nuclear factor, erythroid derived 2, like 2

multiple interactions
increases expression

ISO

ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]]
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 protein]; Acetylcysteine inhibits the reaction [ferrous sulfate affects the localization of NFE2L2 protein]; ferrous sulfate results in increased expression of and affects the localization of NFE2L2 protein

PMID:26945724 PMID:28583816

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

EXP
ISO

[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein; [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein]

PMID:17879260 PMID:22099153 PMID:23692848

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; Acetylcysteine inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein]

PMID:17172471 PMID:17879260 PMID:28583816

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nitric oxide synthase 2, inducible

multiple interactions

EXP

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

NAD(P)H dehydrogenase, quinone 1

increases expression
multiple interactions

ISO

ferrous sulfate results in increased expression of NQO1 protein
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NQO1 protein]

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

ISO

ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]

NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725

G

prostate transmembrane protein, androgen induced 1

increases expression

ISO

ferrous sulfate results in increased expression of PMEPA1 mRNA

NCBI chr 2:173,066,251...173,118,329
Ensembl chr 2:173,066,251...173,118,326

G

paraoxonase 1

multiple interactions

ISO

[Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]; [Ascorbic Acid co-treated with ferrous sulfate] results in decreased activity of PON1 protein

PMID:12871208 PMID:15375178

NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

ISO

ferrous sulfate results in increased expression of PTGS2 protein
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of PTGS2 protein]

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions
affects localization

EXP
ISO

[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]
ferrous sulfate affects the localization of RELA protein
2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate affects the localization of RELA protein]; Acetylcysteine inhibits the reaction [ferrous sulfate affects the localization of RELA protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein; [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein]

PMID:17879260 PMID:22099153 PMID:23692848 PMID:28583816

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

selectin, platelet (p-selectin) ligand

increases expression

ISO

ferrous sulfate results in increased expression of SELPLG mRNA

NCBI chr 5:113,955,859...113,970,576
Ensembl chr 5:113,956,597...113,970,705

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2

decreases expression

ISO

ferrous sulfate results in decreased expression of SLC11A2 mRNA

NCBI chr15:100,285,779...100,322,090
Ensembl chr15:100,285,779...100,322,953

G

solute carrier family 40 (iron-regulated transporter), member 1

multiple interactions

EXP

SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased abundance of Reactive Oxygen Species]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron]

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

synuclein, alpha

multiple interactions

ISO

ferrous sulfate inhibits the reaction [SNCA protein results in decreased abundance of Glutathione]; ferrous sulfate inhibits the reaction [SNCA protein results in decreased expression of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased activity of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased expression of GCLC protein]; ferrous sulfate promotes the reaction [SNCA protein results in increased abundance of Reactive Oxygen Species]

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

superoxide dismutase 1, soluble

multiple interactions
decreases activity

ISO

ferrous sulfate inhibits the reaction [SNCA protein results in decreased expression of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased activity of SOD1 protein]
ferrous sulfate results in decreased activity of SOD1 protein

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

decreases expression
increases activity

ISO

ferrous sulfate results in decreased expression of SOD2 protein
ferrous sulfate results in increased activity of SOD2 protein

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

secreted phosphoprotein 1

decreases expression

ISO

ferrous sulfate results in decreased expression of SPP1 mRNA

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

G

signal transducer and activator of transcription 1

increases phosphorylation

ISO

ferrous sulfate results in increased phosphorylation of STAT1 protein

NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024

G

signal transducer and activator of transcription 3

multiple interactions

ISO

[ferrous sulfate co-treated with Copper Sulfate] promotes the reaction [Hydrogen Peroxide affects the localization of STAT3 protein]

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

synaptophysin

multiple interactions

ISO

(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein

NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495

G

taste receptor, type 1, member 3

affects response to substance

EXP

TAS1R3 protein affects the susceptibility to ferrous sulfate

NCBI chr 4:155,943,725...155,947,810
Ensembl chr 4:155,943,725...155,947,819

G

transferrin receptor

decreases expression

ISO

ferrous sulfate results in decreased expression of TFRC mRNA
ferrous sulfate results in decreased expression of TFRC protein

PMID:10966897 PMID:16039939 PMID:28993186

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

G

tissue inhibitor of metalloproteinase 1

multiple interactions
increases expression

ISO

Diltiazem inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]; Nimodipine inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]; Verapamil inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

toll-like receptor 2

multiple interactions

EXP

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]

NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074

G

toll-like receptor 4

multiple interactions

EXP

[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

increases expression
multiple interactions
increases secretion

ISO
EXP

ferrous sulfate results in increased expression of TNF mRNA; ferrous sulfate results in increased expression of TNF protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased secretion of TNF protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of TNF protein]; Dimethyl Sulfoxide inhibits the reaction [ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]]; ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; tetramethylthiourea inhibits the reaction [ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]]; U 0126 inhibits the reaction [ferrous sulfate results in increased secretion of TNF protein]
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein]
ferrous sulfate inhibits the reaction [Deferoxamine results in decreased activity of TNF protein]; ferrous sulfate inhibits the reaction [Mimosine results in decreased activity of TNF protein]

PMID:7539275 PMID:15550384 PMID:15963385 PMID:17172471 PMID:19428942 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

TNFRSF1A-associated via death domain

decreases expression

ISO

ferrous sulfate results in decreased expression of TRADD mRNA

NCBI chr 8:105,985,207...105,991,226
Ensembl chr 8:105,984,918...105,991,241

G

transferrin

multiple interactions
increases expression

ISO

ferrous sulfate promotes the reaction [TF protein results in increased uptake of Iron]
ferrous sulfate results in increased expression of TF protein

PMID:11335103 PMID:28993186

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

transient receptor potential cation channel, subfamily M, member 5

affects response to substance

EXP

TRPM5 protein affects the susceptibility to ferrous sulfate

NCBI chr 7:142,625,266...142,648,379
Ensembl chr 7:142,622,890...142,648,379

G

transient receptor potential cation channel, subfamily V, member 1

increases activity

ISO

ferrous sulfate results in increased activity of TRPV1 protein

NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068

G

chemokine (C motif) receptor 1

decreases expression

ISO

ferrous sulfate results in decreased expression of XCR1 mRNA

NCBI chr 9:123,681,380...123,691,094
Ensembl chr 9:123,681,380...123,691,094

iron(3+) sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

multiple interactions

ISO

ferric sulfate inhibits the reaction [Nickel results in increased activity of ACO1 protein]

NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions
increases activity

ISO

Capsaicin inhibits the reaction [ferric sulfate results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [ferric sulfate results in increased activity of GOT1 protein]

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glutamic pyruvic transaminase, soluble

multiple interactions
increases activity

ISO

Capsaicin inhibits the reaction [ferric sulfate results in increased activity of GPT protein]; Curcumin inhibits the reaction [ferric sulfate results in increased activity of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

ISO

ferric sulfate inhibits the reaction [Nickel results in increased stability of HIF1A protein]

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

iron(III) citrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

multiple interactions
increases secretion
increases expression

ISO

Alcohols inhibits the reaction [ferric citrate results in increased expression of ALB mRNA]; Alcohols inhibits the reaction [ferric citrate results in increased secretion of ALB protein]; ferric citrate inhibits the reaction [Alcohols results in increased expression of ALB mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased secretion of ALB protein]

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldolase B, fructose-bisphosphate

multiple interactions
increases expression

ISO

Alcohols inhibits the reaction [ferric citrate results in increased expression of ALDOB mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased expression of ALDOB mRNA]

NCBI chr 4:49,535,993...49,549,546
Ensembl chr 4:49,535,995...49,549,546

G

aquaporin 4

decreases expression

ISO

ferric citrate results in decreased expression of AQP4 mRNA

NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039

G

carbonic anhydrase 9

decreases expression

ISO

ferric citrate results in decreased expression of CA9 mRNA

NCBI chr 4:43,507,026...43,513,729
Ensembl chr 4:43,506,966...43,513,729

G

C-C motif chemokine ligand 2

decreases expression

ISO

ferric citrate results in decreased expression of CCL2 mRNA

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

cystic fibrosis transmembrane conductance regulator

decreases expression

ISO

ferric citrate results in decreased expression of CFTR mRNA

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

C-reactive protein, pentraxin-related

increases expression

ISO

ferric citrate results in increased expression of CRP mRNA

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

C-X-C motif chemokine ligand 15

multiple interactions
decreases expression

ISO

ferric citrate inhibits the reaction [Deferoxamine results in increased expression of CXCL8 mRNA]; ferric citrate inhibits the reaction [Deferoxamine results in increased secretion of CXCL8 protein]
ferric citrate results in decreased expression of CXCL8 mRNA

PMID:17097691 PMID:29959986

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases expression

ISO

Alcohols inhibits the reaction [ferric citrate results in increased expression of CYP2E1 mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased expression of CYP2E1 mRNA]

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

DNA-damage inducible transcript 3

multiple interactions

ISO

[trigonelline co-treated with ferric citrate] results in increased expression of DDIT3 mRNA

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

endothelin 1

decreases expression

ISO

ferric citrate results in decreased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

erythropoietin

increases expression

ISO

ferric citrate results in increased expression of EPO mRNA

NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504

G

coagulation factor X

decreases activity

ISO

ferric citrate results in decreased activity of F10 protein

NCBI chr 8:13,087,308...13,106,676
Ensembl chr 8:13,087,308...13,106,676

G

coagulation factor II

decreases activity

ISO

ferric citrate results in decreased activity of F2 protein

NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759

G

ferritin heavy polypeptide 1

increases expression
multiple interactions

ISO

ferric citrate results in increased expression of FTH1 mRNA
[trigonelline co-treated with ferric citrate] results in increased expression of FTH1 mRNA

NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462

G

ferritin light polypeptide 1

multiple interactions

ISO

[trigonelline co-treated with ferric citrate] results in increased expression of FTL mRNA

NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308

G

glutamate-cysteine ligase, modifier subunit

increases expression

ISO

ferric citrate results in increased expression of GCLM mRNA

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

EXP
ISO

ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]
ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Quercetin results in increased expression of HIF1A mRNA]; ferric citrate inhibits the reaction [Quercetin results in increased expression of HIF1A protein]

PMID:16527254 PMID:17015263 PMID:17364964

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

heme oxygenase 1

increases expression

ISO

ferric citrate results in increased expression of HMOX1 mRNA

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

interleukin 1 alpha

decreases expression

ISO

ferric citrate results in decreased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 6

decreases expression
multiple interactions

ISO

iron supplemented diet decreases expression of IL6 mRNA in liver
iron supplemented diet inhibited the reaction [ethanol increases expression of IL6 mRNA in maternal and fetal liver]

RGD

PMID:31524964 PMID:31524964

RGD:598092517, RGD:598092517

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

kelch-like ECH-associated protein 1

multiple interactions

ISO

[trigonelline co-treated with ferric citrate] results in decreased expression of KEAP1 mRNA

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

kallikrein 1

decreases activity

ISO

ferric citrate results in decreased activity of KLK1 protein

NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042

G

nuclear factor, erythroid derived 2, like 2

multiple interactions
affects localization

ISO

trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

NAD(P)H dehydrogenase, quinone 1

increases expression
multiple interactions

ISO

ferric citrate results in increased expression of NQO1 mRNA; ferric citrate results in increased expression of NQO1 protein
trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

EXP
ISO

ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein]

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

decreases expression

ISO

ferric citrate results in decreased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

sequestosome 1

increases expression

ISO

ferric citrate results in increased expression of SQSTM1 mRNA

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

transferrin receptor

multiple interactions
increases expression

ISO

ferric citrate inhibits the reaction [Quercetin results in increased expression of TFRC protein]
ferric citrate results in increased expression of TFRC protein

PMID:17364964 PMID:29959986

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

G

tumor necrosis factor

decreases expression

ISO

ferric citrate results in decreased expression of TNF mRNA

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transferrin

increases expression

ISO

ferric citrate results in increased expression of TF mRNA

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

thioredoxin reductase 1

increases expression

ISO

ferric citrate results in increased expression of TXNRD1 mRNA

NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546

iron(III) nitrilotriacetate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 1A

multiple interactions

ISO

ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased expression of ABCB1 protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased expression of ABCB1 protein]

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family C member 1

increases expression

EXP

ferric nitrilotriacetate results in increased expression of ABCC1 mRNA

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP-binding cassette, sub-family member 2

increases expression

EXP

ferric nitrilotriacetate results in increased expression of ABCC2 mRNA

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 4

increases expression

EXP

ferric nitrilotriacetate results in increased expression of ABCC4 mRNA

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

annexin A2

increases expression

ISO

ferric nitrilotriacetate results in increased expression of ANXA2 mRNA

NCBI chr 9:69,360,978...69,399,074
Ensembl chr 9:69,360,902...69,399,077

G

BCL2-associated X protein

increases expression

ISO

ferric nitrilotriacetate results in increased expression of BAX mRNA

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

BCL2 binding component 3

increases expression

ISO

ferric nitrilotriacetate results in increased expression of BBC3 mRNA

NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130

G

BCL2-interacting killer

increases expression

ISO

ferric nitrilotriacetate results in increased expression of BIK mRNA

NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835

G

caldesmon 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of CALD1 mRNA

NCBI chr 6:34,575,433...34,752,404
Ensembl chr 6:34,575,435...34,752,408

G

calnexin

increases expression

ISO

ferric nitrilotriacetate results in increased expression of CANX protein

NCBI chr11:50,184,784...50,216,500
Ensembl chr11:50,184,788...50,216,500

G

caspase 12

increases expression

ISO

ferric nitrilotriacetate results in increased expression of CASP12 mRNA

NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032

G

caspase 3

multiple interactions

ISO

[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

multiple interactions

ISO

[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA]

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

multiple interactions

ISO

[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA]

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

catalase

multiple interactions
decreases activity

ISO

[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein; chrysin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; geraniol inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]

PMID:9667754 PMID:15198074 PMID:18684806 PMID:21907755 PMID:23194824 More...

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cyclin D1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of CCND1 mRNA; ferric nitrilotriacetate results in increased expression of CCND1 protein

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

CD44 antigen

increases expression

ISO

ferric nitrilotriacetate results in increased expression of CD44 mRNA; ferric nitrilotriacetate results in increased expression of CD44 protein

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

CD47 antigen (Rh-related antigen, integrin-associated signal transducer)

increases expression

ISO

ferric nitrilotriacetate results in increased expression of CD47 mRNA

NCBI chr16:49,671,691...49,732,799
Ensembl chr16:49,620,896...49,735,373

G

cyclin dependent kinase inhibitor 1A

increases expression

ISO

ferric nitrilotriacetate results in increased expression of CDKN1A mRNA

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cholinergic receptor, muscarinic 1, CNS

decreases expression

ISO

ferric nitrilotriacetate results in decreased expression of CHRM1 mRNA

NCBI chr19:8,641,369...8,660,970
Ensembl chr19:8,641,153...8,660,951

G

cholinergic receptor, muscarinic 2, cardiac

decreases expression

ISO

ferric nitrilotriacetate results in decreased expression of CHRM2 mRNA

NCBI chr 6:36,364,928...36,505,573
Ensembl chr 6:36,365,019...36,505,349

G

collagen, type I, alpha 1

increases expression
multiple interactions

ISO

ferric nitrilotriacetate results in increased expression of COL1A1 protein
ethylisopropylamiloride inhibits the reaction [ferric nitrilotriacetate results in increased expression of COL1A1 protein]

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

cytoglobin

multiple interactions

ISO

CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]

NCBI chr11:116,536,421...116,544,887
Ensembl chr11:116,536,421...116,545,139

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

ISO

[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]

PMID:12086689 PMID:17034788 PMID:21352821

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

FBJ osteosarcoma oncogene

increases expression

ISO

ferric nitrilotriacetate results in increased expression of FOS mRNA

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

fos-like antigen 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of FOSL1 mRNA; ferric nitrilotriacetate results in increased expression of FOSL1 protein

NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974

G

glucose-6-phosphate dehydrogenase X-linked

decreases activity

ISO

ferric nitrilotriacetate results in decreased activity of G6PD protein

NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800

G

glutamate-cysteine ligase, catalytic subunit

increases expression

EXP

ferric nitrilotriacetate results in increased expression of GCLC mRNA

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutathione reductase

decreases activity
multiple interactions

ISO

ferric nitrilotriacetate results in decreased activity of GSR protein
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of GSR protein]

PMID:9667754 PMID:15198074 PMID:30098279

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

glutathione S-transferase, alpha 4

increases expression

EXP

ferric nitrilotriacetate results in increased expression of GSTA4 mRNA; ferric nitrilotriacetate results in increased expression of GSTA4 protein

NCBI chr 9:78,099,248...78,116,631
Ensembl chr 9:78,090,056...78,116,631

G

G two S phase expressed protein 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of GTSE1 mRNA

NCBI chr15:85,743,928...85,760,774
Ensembl chr15:85,743,946...85,760,774

G

hepatitis A virus cellular receptor 1

multiple interactions

ISO

[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein]

PMID:21907755 PMID:30098279

NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

ISO

ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased activity of HIF1A protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased activity of HIF1A protein]

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

heme oxygenase 1

increases expression

ISO
EXP

ferric nitrilotriacetate results in increased expression of HMOX1 mRNA

PMID:18617210 PMID:19490752

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heat shock protein 90, alpha (cytosolic), class A member 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of HSP90AA1 mRNA

NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162

G

interleukin 24

increases expression

ISO

ferric nitrilotriacetate results in increased expression of IL24 mRNA

NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191

G

interleukin 6

increases expression
multiple interactions

EXP
ISO

ferric nitrilotriacetate results in increased expression of IL6 protein
ferric nitrilotriacetate results in increased expression of IL6 mRNA
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein]

PMID:15781289 PMID:19490752 PMID:23194824

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

jun proto-oncogene

increases expression

ISO

ferric nitrilotriacetate results in increased expression of JUN mRNA; ferric nitrilotriacetate results in increased expression of JUN protein

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

keratin 18

multiple interactions

ISO

[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein

NCBI chr15:101,936,651...101,940,461
Ensembl chr15:101,936,615...101,940,462

G

keratin 8

multiple interactions

ISO

[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein

NCBI chr15:101,905,146...101,912,777
Ensembl chr15:101,905,133...101,912,917

G

minichromosome maintenance complex component 3

increases expression

ISO

ferric nitrilotriacetate results in increased expression of MCM3 mRNA

NCBI chr 1:20,873,188...20,890,536
Ensembl chr 1:20,873,192...20,890,536

G

metallothionein 1

multiple interactions

EXP

[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Cadmium]; [ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Zinc]; ferric nitrilotriacetate results in increased oxidation of [MT1 protein binds to Zinc]

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 2

multiple interactions

EXP

[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT2 protein binds to Cadmium]

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

metallothionein 3

decreases response to substance

ISO

MT3 protein results in decreased susceptibility to ferric nitrilotriacetate

NCBI chr 8:94,879,235...94,880,776
Ensembl chr 8:94,879,235...94,880,774

G

myelocytomatosis oncogene

increases expression

ISO

ferric nitrilotriacetate results in increased expression of MYC mRNA; ferric nitrilotriacetate results in increased expression of MYC protein

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

nuclear factor, erythroid derived 2, like 2

affects localization

EXP

ferric nitrilotriacetate affects the localization of NFE2L2 protein

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

ISO

[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA]

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nitric oxide synthase 2, inducible

multiple interactions
increases expression

EXP
ISO

ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein]; ferric nitrilotriacetate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
ferric nitrilotriacetate results in increased expression of NOS2 protein
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of NOS2 protein]; ferric nitrilotriacetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

PMID:11461780 PMID:11746204 PMID:12490132 PMID:23194824

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

NAD(P)H dehydrogenase, quinone 1

increases expression

EXP

ferric nitrilotriacetate results in increased expression of NQO1 mRNA; ferric nitrilotriacetate results in increased expression of NQO1 protein

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

ornithine decarboxylase, structural 1

multiple interactions
increases activity

ISO

[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein]; Vitamin E inhibits the reaction [ferric nitrilotriacetate results in increased activity of ODC1 protein]

PMID:9667754 PMID:14623030 PMID:15949125

NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506

G

phosphoenolpyruvate carboxykinase 1, cytosolic

increases expression

ISO

ferric nitrilotriacetate results in increased expression of PCK1 mRNA

NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066

G

proliferating cell nuclear antigen

multiple interactions

ISO

[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein]

PMID:21907755 PMID:23194824

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

pleckstrin homology like domain, family A, member 3

increases expression

ISO

ferric nitrilotriacetate results in increased expression of PHLDA3 mRNA

NCBI chr 1:135,693,823...135,696,872
Ensembl chr 1:135,693,857...135,696,874

G

plasminogen activator, urokinase

multiple interactions
increases expression
increases activity

ISO

Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA]

NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453

G

polo like kinase 2

increases expression

ISO

ferric nitrilotriacetate results in increased expression of PLK2 mRNA

NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378

G

polymerase (DNA directed), alpha 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of POLA1 mRNA

NCBI chr X:92,348,372...92,675,993
Ensembl chr X:92,348,373...92,675,761

G

peptidylprolyl isomerase A

increases expression

ISO

ferric nitrilotriacetate results in increased expression of PPIA protein

NCBI chr11:6,365,867...6,369,817
Ensembl chr11:6,365,443...6,369,817

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

ISO

[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]

PMID:23194824 PMID:30098279

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

protein tyrosine phosphatase receptor type B

decreases expression

ISO

ferric nitrilotriacetate results in decreased expression of PTPRB mRNA

NCBI chr10:116,111,407...116,225,443
Ensembl chr10:116,111,428...116,225,440

G

protein tyrosine phosphatase receptor type Z, polypeptide 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of PTPRZ1 mRNA; ferric nitrilotriacetate results in increased expression of PTPRZ1 protein

NCBI chr 6:22,875,302...23,052,915
Ensembl chr 6:22,875,501...23,052,915

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

ISO

[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

ribosomal protein L19

increases expression

ISO

ferric nitrilotriacetate results in increased expression of RPL19 mRNA

NCBI chr11:97,912,829...97,921,319
Ensembl chr11:97,917,536...97,921,318

G

reprimo, TP53 dependent G2 arrest mediator candidate

increases expression

ISO

ferric nitrilotriacetate results in increased expression of RPRM mRNA

NCBI chr 2:53,974,105...53,975,564
Ensembl chr 2:53,974,105...53,975,564

G

ribosomal protein S13

increases expression

ISO

ferric nitrilotriacetate results in increased expression of RPS13 mRNA

NCBI chr 7:115,930,742...115,933,425
Ensembl chr 7:115,930,740...115,933,430

G

ribosomal protein S15

increases expression

ISO

ferric nitrilotriacetate results in increased expression of RPS15 mRNA

NCBI chr10:80,128,265...80,129,948
Ensembl chr10:80,128,287...80,129,948

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2

decreases expression

ISO

ferric nitrilotriacetate results in decreased expression of SLC11A2 mRNA

NCBI chr15:100,285,779...100,322,090
Ensembl chr15:100,285,779...100,322,953

G

solute carrier family 40 (iron-regulated transporter), member 1

decreases expression

ISO

ferric nitrilotriacetate results in decreased expression of SLC40A1 mRNA

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

superoxide dismutase 1, soluble

multiple interactions

ISO

ferric nitrilotriacetate inhibits the reaction [Dimethylnitrosamine results in decreased expression of SOD1 protein]

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

structure specific recognition protein 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of SSRP1 mRNA

NCBI chr 2:84,867,519...84,877,453
Ensembl chr 2:84,867,578...84,877,453

G

transforming growth factor alpha

increases expression

ISO

ferric nitrilotriacetate results in increased expression of TGFA mRNA; ferric nitrilotriacetate results in increased expression of TGFA protein

NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701

G

transforming growth factor, beta 1

multiple interactions

ISO

[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta 2

increases expression

ISO

ferric nitrilotriacetate results in increased expression of TGFB2 mRNA

NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186

G

tissue inhibitor of metalloproteinase 1

multiple interactions

ISO

[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

tumor necrosis factor

increases expression
multiple interactions

EXP
ISO

ferric nitrilotriacetate results in increased expression of TNF protein
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein]

PMID:15781289 PMID:23194824

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

multiple interactions

ISO

[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thioredoxin 1

increases expression

ISO

ferric nitrilotriacetate results in increased expression of TXN protein

NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411

G

thioredoxin interacting protein

decreases expression
increases methylation

ISO

ferric nitrilotriacetate results in decreased expression of TXNIP protein
ferric nitrilotriacetate results in increased methylation of TXNIP promoter

NCBI chr 3:96,465,273...96,469,173
Ensembl chr 3:96,465,273...96,469,199

G

ubiquitin D

increases expression

ISO

ferric nitrilotriacetate results in increased expression of UBD mRNA

NCBI chr17:37,504,783...37,506,992
Ensembl chr17:37,504,783...37,506,986

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2-associated X protein

increases expression

ISO

nickel ferrite analog results in increased expression of BAX mRNA; nickel ferrite results in increased expression of BAX mRNA

PMID:21382431 PMID:25966046

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

decreases expression

ISO

nickel ferrite analog results in decreased expression of BCL2 mRNA; nickel ferrite results in decreased expression of BCL2 mRNA

PMID:21382431 PMID:25966046

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

baculoviral IAP repeat-containing 5

decreases expression

ISO

nickel ferrite results in decreased expression of BIRC5 mRNA

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

caspase 3

increases activity
increases expression

ISO

nickel ferrite analog results in increased activity of CASP3 protein; nickel ferrite results in increased activity of CASP3 protein
nickel ferrite analog results in increased expression of CASP3 mRNA; nickel ferrite results in increased expression of CASP3 mRNA

PMID:21382431 PMID:25966046

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 9

increases activity
increases expression

ISO

nickel ferrite analog results in increased activity of CASP9 protein; nickel ferrite results in increased activity of CASP9 protein
nickel ferrite analog results in increased expression of CASP9 mRNA; nickel ferrite results in increased expression of CASP9 mRNA

PMID:21382431 PMID:25966046

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

transformation related protein 53

increases expression

ISO

nickel ferrite analog results in increased expression of TP53 mRNA; nickel ferrite results in increased expression of TP53 mRNA

PMID:21382431 PMID:25966046

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22426
chemical entity	22425
molecular entity	22420
elemental molecular entity	18461
elemental iron	528
iron cation +	225
iron(0) +	398
Path 2
Term	Annotations
CHEBI ontology	22426
subatomic particle	22420
composite particle	22420
hadron	22420
baryon	22420
nucleon	22420
atomic nucleus	22420
atom	22420
metal atom	19453
transition element atom	18738
d-block element atom	18734
d-block molecular entity	18580
iron group molecular entity	1734
iron molecular entity	1717
elemental iron	528
iron cation +	225
iron(0) +	398

paths to the root